Substances that inhibit or prevent the proliferation of NEOPLASMS.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
Alkaloids derived from TYRAMINE combined with 3,4-dihydroxybenzaldehyde via a norbelladine pathway, including GALANTAMINE, lycorine and crinine. They are found in the Amaryllidaceae (LILIACEAE) plant family.
A plant genus of the family LILIACEAE. Members contain ungiminorine and LECTINS.
Pyrido-CARBAZOLES originally discovered in the bark of OCHROSIA ELLIPTICA. They inhibit DNA and RNA synthesis and have immunosuppressive properties.
Compounds with 1,2-diphenylethane. They are structurally like reduced STILBENES.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
A group of 20-member macrolactones in which there are three remotely substituted pyran rings that are linked by a methylene bridge and an E-disubstituted alkene, and have geminal dimethyls at C8 and C18 carbons. Some interact with PROTEIN KINASE C.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.
Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
The action of a drug in promoting or enhancing the effectiveness of another drug.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Acridines which are substituted in any position by one or more amino groups or substituted amino groups.
A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).
A cell line derived from cultured tumor cells.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES.
Antimetabolites that are useful in cancer chemotherapy.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
A group of often glycosylated macrocyclic compounds formed by chain extension of multiple PROPIONATES cyclized into a large (typically 12, 14, or 16)-membered lactone. Macrolides belong to the POLYKETIDES class of natural products, and many members exhibit ANTIBIOTIC properties.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Organic compounds that contain 1,2-diphenylethylene as a functional group.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Tumors or cancer of the LUNG.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Tumors or cancer of the human BREAST.
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
Elements of limited time intervals, contributing to particular results or situations.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Established cell cultures that have the potential to propagate indefinitely.
The rate dynamics in chemical or physical systems.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the COLON.
A family of intracellular CYSTEINE ENDOPEPTIDASES that play a role in regulating INFLAMMATION and APOPTOSIS. They specifically cleave peptides at a CYSTEINE amino acid that follows an ASPARTIC ACID residue. Caspases are activated by proteolytic cleavage of a precursor form to yield large and small subunits that form the enzyme. Since the cleavage site within precursors matches the specificity of caspases, sequential activation of precursors by activated caspases can occur.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Tumors or cancer of the PROSTATE.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of signal transduction and gene expression, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Coverings for the hands, usually with separations for the fingers, made of various materials, for protection against infections, toxic substances, extremes of hot and cold, radiations, water immersion, etc. The gloves may be worn by patients, care givers, housewives, laboratory and industrial workers, police, etc.
A plant genus of the family ASTERACEAE. This plant should not be confused with microtubule asters (MICROTUBULES) nor with aster yellows phytoplasma (mycoplasma-like organisms).
The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation.
A small plant family of the order Santalales, subclass Rosidae, class Magnoliopsida.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Individuals responsible for various duties pertaining to the medical office routine.
A nursing specialty concerned with the care provided to cancer patients. It includes aspects of family functioning through education of both patient and family.
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
Devices designed to provide personal protection against injury to individuals exposed to hazards in industry, sports, aviation, or daily activities.
Functions and activities of DENTITION as a whole.
Any materials used in providing care specifically in the hospital.
Clothing designed to protect the individual against possible exposure to known hazards.
The presence of an infectious agent on instruments, prostheses, or other inanimate articles.
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
The removal of contaminating material, such as radioactive materials, biological materials, or CHEMICAL WARFARE AGENTS, from a person or object.
Inorganic compounds that contain vanadium as an integral part of the molecule.
Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).
Personnel who provide nursing service to patients in a hospital.
The monitoring of the level of toxins, chemical pollutants, microbial contaminants, or other harmful substances in the environment (soil, air, and water), workplace, or in the bodies of people and animals present in that environment.
Elements, compounds, mixtures, or solutions that are considered severely harmful to human health and the environment. They include substances that are toxic, corrosive, flammable, or explosive.
The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
The individuals employed by the hospital.
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
The preparation, mixing, and assembling of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814)
An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
Clinical protocols used to inhibit the growth or spread of NEOPLASMS.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Facilities for the preparation and dispensing of drugs.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
Simultaneous resistance to several structurally and functionally distinct drugs.
An enzyme that catalyzes the synthesis of geranylgeranyl diphosphate from trans, trans-farnesyl diphosphate and isopentenyl diphosphate.
The hospital department responsible for the administration and provision of diagnostic and therapeutic services for the cancer patient.
A genotoxicological technique for measuring DNA damage in an individual cell using single-cell gel electrophoresis. Cell DNA fragments assume a "comet with tail" formation on electrophoresis and are detected with an image analysis system. Alkaline assay conditions facilitate sensitive detection of single-strand damage.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.
A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.
Professionals qualified by graduation from an accredited school of nursing and by passage of a national licensing examination to practice nursing. They provide services to patients requiring assistance in recovering or maintaining their physical or mental health.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
Institutions with an organized medical staff which provide medical care to patients.
Organic nitrogenous bases. Many alkaloids of medical importance occur in the animal and vegetable kingdoms, and some have been synthesized. (Grant & Hackh's Chemical Dictionary, 5th ed)
Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Compounds that inhibit the activity of DNA TOPOISOMERASE I.
A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
The products of chemical reactions that result in the addition of extraneous chemical groups to DNA.
DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Those persons legally qualified by education and training to engage in the practice of pharmacy.
The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.
Keto-pyrans.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Tests of chemical substances and physical agents for mutagenic potential. They include microbial, insect, mammalian cell, and whole animal tests.
Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion.
Human colonic ADENOCARCINOMA cells that are able to express differentiation features characteristic of mature intestinal cells such as the GOBLET CELLS.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed)
A group of compounds that contain the structure SO2NH2.
DNA present in neoplastic tissue.
A general term for various neoplastic diseases of the lymphoid tissue.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
An antimitotic agent with immunosuppressive properties.
Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
Organic compounds which contain platinum as an integral part of the molecule.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
A transferase that catalyzes the addition of aliphatic, aromatic, or heterocyclic FREE RADICALS as well as EPOXIDES and arene oxides to GLUTATHIONE. Addition takes place at the SULFUR. It also catalyzes the reduction of polyol nitrate by glutathione to polyol and nitrite.
An alkylating agent of value against both hematologic malignancies and solid tumors.
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
The reversibly oxidized form of ascorbic acid. It is the lactone of 2,3-DIKETOGULONIC ACID and has antiscorbutic activity in man on oral ingestion.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Institutions specializing in the care of cancer patients.

Electronic volume analysis of L1210 chemotherapy. (1/35913)

The rapid analysis of in vivo chemotherapy on the L1210 ascites tumor grown in C57BL/6 X DBA/2F1 mice has been shown by means of an electronic volume analysis. The drugs were injected on the 4th day of tumor growth, and the cells in the peritoneal cavity were studied at 24-hr intervals on the 5th through 7th day. Using the electronic cell volume distributions, combined with labeling indices, cell morphology, and cell counts, it was found that the alkylating agents. 1,3-bis(2-chloroethyl)-1-nitrosourea and cyclophosphamide, at the dosages used, were more effective than the S-phase-specific drugs, palmitoyl ester of 1-beta-D-arabinofuranosylcytosine, vincristine, and methotrexate.  (+info)

Various forms of chemically induced liver injury and their detection by diagnostic procedures. (2/35913)

A large number of chemical agents, administered for therapeutic or diagnostic purposes, can produce various types of hepatic injury by several mechanisms. Some agents are intrinsically hepatotoxic, and others produce hepatic injury only in the rare, uniquely susceptible individual. Idiosyncrasy of the host is the mechanism for most types of drug-induced hepatic injury. It may reflect allergy to the drug or a metabolic aberation of the host permitting the accumulation of hepatotoxic metabolites. The syndromes of hepatic disease produced by drugs have been classified hepatocellular, hepatocanalicular, mixed and canalicular. Measurement of serum enzyme activities has provided a powerful tool for studies of hepatotoxicity. Their measurement requires awareness of relative specificity, knowledge of the mechanisms involved, and knowledge of the relationship between known hepatotoxic states and elevated enzyme activities.  (+info)

Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. (3/35913)

The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response. We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for > 3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues. Global transcription is not inhibited: p21waf-1/cip1 and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent. When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated. Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.  (+info)

Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. (4/35913)

Primary blasts of a t(11;17)(q23;q21) acute promyelocytic leukaemia (APL) patient were analysed with respect to retinoic acid (RA) and arsenic trioxide (As2O3) sensitivity as well as PLZF/RARalpha status. Although RA induced partial monocytic differentiation ex vivo, but not in vivo, As203 failed to induce apoptosis in culture, contrasting with t(15;17) APL and arguing against the clinical use of As203 in t(11;17)(q23;q21) APL. Prior to cell culture, PLZF/RARalpha was found to exactly co-localize with PML onto PML nuclear bodies. However upon cell culture, it quickly shifted towards microspeckles, its localization found in transfection experiments. Arsenic trioxide, known to induce aggregation of PML nuclear bodies, left the microspeckled PLZF/RARalpha localization completely unaffected. RA treatment led to PLZF/RARalpha degradation. However, this complete PLZF/RARalpha degradation was not accompanied by differentiation or apoptosis, which could suggest a contribution of the reciprocal RARalpha/PLZF fusion product in leukaemogenesis or the existence of irreversible changes induced by the chimera.  (+info)

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. (5/35913)

Interleukin 6 (IL-6) is the major survival factor for myeloma tumor cells and induces signaling through the STAT proteins. We report that one STAT family member, Stat3, is constitutively activated in bone marrow mononuclear cells from patients with multiple myeloma and in the IL-6-dependent human myeloma cell line U266. Moreover, U266 cells are inherently resistant to Fas-mediated apoptosis and express high levels of the antiapoptotic protein Bcl-xL. Blocking IL-6 receptor signaling from Janus kinases to the Stat3 protein inhibits Bcl-xL expression and induces apoptosis, demonstrating that Stat3 signaling is essential for the survival of myeloma tumor cells. These findings provide evidence that constitutively activated Stat3 signaling contributes to the pathogenesis of multiple myeloma by preventing apoptosis.  (+info)

Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (6/35913)

Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals.  (+info)

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. (7/35913)

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8-7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues.  (+info)

Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. (8/35913)

Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise.  (+info)

Docetaxel is used seeing that an effective chemotherapeutic agent in breasts cancer tumor treatment commonly, but the underlying mechanisms of drug level of resistance are not really understood fully. overexpression enhanced MCF-7 and MDA-MB-231 cell level of resistance to docetaxel. Ectopic miR-129 reflection decreased CP110 reflection and the luciferase activity of a CP110 3 untranslated region-based news reporter build in MDA-MB-231 cells, recommending that CP110 is normally a immediate miR-129-3p focus on. We shown that repair of CP110 appearance in MDA-MB-231 and MCF-7 cells by miR-129 overexpression made the cells delicate to docetaxel. In a naked xenograft model, miR-129 up-regulation considerably reduced MDA-MB-231 cells response to docetaxel. Our results recommend that miR-129-3p down-regulation possibly sensitizes breasts tumor cells to docetaxel treatment. Breasts tumor is definitely one of the most common tumor types and the primary trigger of tumor loss of life in ladies ...
TY - JOUR. T1 - Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital. AU - Hann, A. AU - Bohle, W. AU - Egger, Jan. AU - Zoller, W G. N1 - © Georg Thieme Verlag KG Stuttgart · New York.. PY - 2016/10. Y1 - 2016/10. N2 - Background: New chemotherapeutic strategies for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) have been shown to improve survival in randomized clinical trials. Little is known about the use of such chemotherapies and their benefit in community-based hospitals. This retrospective study analyzes the overall survival of these patients under real life conditions before and after the introduction of FOLFIRINOX in 2011. Methods: We retrospectively identified consecutive patients with PDAC who were treated at our hospital from 2011 to June 2014 (2011+ cohort) and 2004 to 2010 (historical cohort). Patients were included if PDAC was diagnosed in a locally advanced or metastatic ...
TY - JOUR. T1 - A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. AU - Adjei, Alex A.. PY - 1999/9/14. Y1 - 1999/9/14. N2 - Colorectal carcinoma is an important cause of cancer morbidity and mortality. 5-fluorouracil has been the major chemotherapeutic agent for the treatment of colorectal carcinoma for the past four decades. This regimen is noncurative, and its impact on survival is unclear. Attempts at identifying more effective chemotherapeutic agents for colorectal cancer have yielded oral formulations and prodrugs of 5-fluorouracil with apparently equivalent efficacy. Specific thymidylate synthase inhibitors are now available. Platinum analogues with activity in colorectal carcinoma, and no cross-resistance to the antimetabolites have also been developed. The topoisomerase I inhibitors represent a new class of agents with a novel mechanism of action. These agents are in phase II and Phase III clinical trials, others have ...
Pembrolizumab may have a manageable toxicity profile and promising antitumor activity in recurrent or metastatic PD-L1-positive gastric cancer.
Vascularization, oxygenation, and metabolism are important parameters of a tumor, determining its development and treatment response. The overall goals of this thesis were to: 1) describe these parameters in colorectal cancer, both in animal models and in humans; 2) explore the possibility to manipulate vascularization, oxygenation and metabolism for the improvement of cytotoxic treatment; 3) monitor uptake and metabolism of fluorinated cytotoxic drugs in colorectal cancer in an early stage of the treatment. The specific questions were addressed whether vascularization as measured by dynamic contrast enhanced MRI (DCE-MRI) and uptake and metabolism of 5-fluorouracil (FU) as measured by fluorine-19 magnetic resonance spectroscopy (19F MRS) could predict response to cytotoxic treatment. This research shows that nicotinamide and carbogen can decrease tumor hypoxia in murine colon carcinoma, both in subcutaneously implanted tumors and in an orthotopic liver metastases model. Moreover, carbogen ...
The adapters IRS1 and IRS2 link growth factor receptors to downstream signaling pathways that regulate proliferation and survival. Both suppress factor-withdrawal-induced apoptosis and have been implicated in cancer progression. However, recent studi
TY - JOUR. T1 - 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. AU - Nepali, Kunal. AU - Kumar, Sunil. AU - Huang, Hsiang Ling. AU - Kuo, Fei Chiao. AU - Lee, Cheng Hsin. AU - Kuo, Ching Chuan. AU - Yeh, Teng Kuang. AU - Li, Yu Hsuan. AU - Chang, Jang Yang. AU - Liou, Jing Ping. AU - Lee, Hsueh Yun. PY - 2015. Y1 - 2015. N2 - This study reports the synthesis of a series of 2-aroylquinoline-5,8-diones (11-23) on the basis of scaffold hopping. The presence of a methoxy group at C6 assists the highly regioselective incorporation with various amines, and simplifies the structural identification process. Among the synthetic compounds, 6-dimethylamino-2-(3,4,5-trimethoxybenzoyl)-quinoline-5,8-dione (12) and 7-pyrrolidin-1-yl-2-(3,4,5-trimethoxybenzoyl)-quinoline-5,8-dione (23) exhibit remarkable anti-proliferative activity against the cancer cell lines tested with mean IC50 values of 0.14 and 0.27 μM, respectively. Compound 23 ...
Signal transducer and activator of transcription 3 (STAT3) plays critical roles in tumorigenesis and malignant evolution and has been intensively studied as a therapeutic target for cancer. A number of STAT3 inhibitors have been evaluated for their antitumor activity in vitro and in vivo in experimental tumor models and several approved therapeutic agents have been reported to function as STAT3 inhibitors. Nevertheless, most STAT3 inhibitors have yet to be translated to clinical evaluation for cancer treatment, presumably because of pharmacokinetic, efficacy, and safety issues. In fact, a major cause of failure of anticancer drug development is lack of efficacy. Genetic interactions among various cancer-related pathways often provide redundant input from parallel and/or cooperative pathways that drives and maintains survival environments for cancer cells, leading to low efficacy of single-target agents. Exploiting genetic interactions of STAT3 with other cancer-related pathways may provide molecular
Signal transducer and activator of transcription 3 (STAT3) plays critical roles in tumorigenesis and malignant evolution and has been intensively studied as a therapeutic target for cancer. A number of STAT3 inhibitors have been evaluated for their antitumor activity in vitro and in vivo in experimental tumor models and several approved therapeutic agents have been reported to function as STAT3 inhibitors. Nevertheless, most STAT3 inhibitors have yet to be translated to clinical evaluation for cancer treatment, presumably because of pharmacokinetic, efficacy, and safety issues. In fact, a major cause of failure of anticancer drug development is lack of efficacy. Genetic interactions among various cancer-related pathways often provide redundant input from parallel and/or cooperative pathways that drives and maintains survival environments for cancer cells, leading to low efficacy of single-target agents. Exploiting genetic interactions of STAT3 with other cancer-related pathways may provide molecular
A breakthrough international trial of a new cancer drug has given researchers renewed hope in the fight against leukaemia, with one Melbourne doctor suggesting it could end traditional chemotherapy treatments for good.
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
New anti-cancer drugs that are used for treating various kinds of cancer like lung cancer, breast cancer, blood cancer, myeloma, bone cancer and brain cancer have been added to IDM
Download Free eBook:Statins Toxic Side Effects: Evidence from 500 scientific papers (Cholesterol) - Free chm, pdf ebooks download
A mysterious form of cell death, coded in proteins and enzymes, led to a discovery by UNC researchers uncovering a prime suspect for new cancer drug development.
BACKGROUND: TNBC is an aggressive breast cancer subtype defined by lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and for which no approved targeted therapies have shown benefit to date. Inhibition of PARP1, a key regulator of DNA repair, has been associated with antitumor activity in both clinical and preclinical settings. Iniparib, a PARP inhibitor, has demonstrated promising efficacy and safety for treatment of patients with metastatic TNBC when combined with gemcitabine (G) and carboplatin (C), two standard chemotherapeutic agents that synergize to induce DNA damage (OShaughnessy et al. SABCS 2009). We hypothesized that by inhibiting DNA repair, iniparib potentiates antiproliferative effects and cell cycle arrest induced by G+C. METHODS: Triple-negative MDA-MB-468(-) cells were selected by fluorescence-activated cell sorting (FACS) of HER2-negative cells. Cells confirmed negative for ER, PR, and HER2 were ...
Drug resistance represents a major obstacle towards the cure of different tumor types including non‐small cell lung cancer (NSCLC), being one of the main causes of failure of antitumor therapy. Tumor cells frequently exhibit simultaneous resistance to multiple structurally unrelated drugs, a phenotype known as multidrug resistance (MDR). A major cause of the MDR phenotype is the over‐expression of members of a conserved family of transmembrane proteins (ABC transporters). Different structurally unrelated compounds, including conventional cytotoxic and target‐specific agents are substrates for ABC transporters. Cancer stem cells (CSC) refer to a subset of tumor cells with the ability to self‐renew and generate the diverse cells that comprise tumors. At present, the mechanisms contributing to the drug‐resistant phenotype of CSC are poorly understood. Some lines of evidence support that specific ABC transporters may be expressed in CSC and may be relevant therapeutic targets. The aim of ...
TY - JOUR. T1 - PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. AU - Fabian, Kellsye P.. AU - Padget, Michelle R.. AU - Donahue, Renee N.. AU - Solocinski, Kristen. AU - Robbins, Yvette. AU - Allen, Clint T.. AU - Lee, John H.. AU - Rabizadeh, Shahrooz. AU - Soon-Shiong, Patrick. AU - Schlom, Jeffrey. AU - Hodge, James W.. PY - 2020/5/20. Y1 - 2020/5/20. N2 - Background Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first time, we report a novel natural killer (NK) cell line, programmed death-ligand 1 (PD-L1) targeting high-affinity natural killer (t-haNK), which was derived from NK-92 and was engineered to express high-affinity CD16, endoplasmic reticulum-retained interleukin (IL)-2, and a ...
A team of scientists is combining sophisticated chemistry and experiments in zebrafish to develop a new cancer drug that shows early potential against melanoma and metastatic breast cancer.
Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under
Anticancer drugs are also called anti-neoplastic agents or chemotherapeutic agents. They act upon rapidly dividing cancer cells and destroy them.
Anticancer drugs are also called anti-neoplastic agents or chemotherapeutic agents. They act upon rapidly dividing cancer cells and destroy them.
TY - JOUR. T1 - Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers. T2 - American society of clinical oncology clinical practice guideline. AU - Hershman, Dawn L.. AU - Lacchetti, Christina. AU - Dworkin, Robert H.. AU - Lavoie Smith, Ellen M.. AU - Bleeker, Jonathan. AU - Cavaletti, Guido. AU - Chauhan, Cynthia. AU - Gavin, Patrick. AU - Lavino, Antoinette. AU - Lustberg, Maryam B.. AU - Paice, Judith. AU - Schneider, Bryan. AU - Smith, Mary Lou. AU - Smith, Tom. AU - Terstriep, Shelby. AU - Wagner-Johnston, Nina. AU - Bak, Kate. AU - Loprinzi, Charles L.. PY - 2014/6/20. Y1 - 2014/6/20. N2 - Purpose: To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. Methods: A systematic literature search identified relevant, randomized controlled trials (RCTs) for the treatment of CIPN. Primary outcomes included incidence and ...
Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and often irreversible condition featuring pain, numbness, tingling and sensitivity to cold in the hands and feet (sometimes progressing to the arms and legs) that afflicts between 30% and 40% of patients undergoing chemotherapy. Chemotherapy drugs associated with CIPN include thalidomide, the epothilones such as ixabepilone, the vinca alkaloids vincristine and vinblastine, the taxanes paclitaxel and docetaxel, the proteasome inhibitors such as bortezomib, and the platinum-based drugs cisplatin, oxaliplatin and carboplatin. Whether CIPN arises, and to what degree, is determined by the choice of drug, duration of use, the total amount consumed and whether the patient already has peripheral neuropathy. Though the symptoms are mainly sensory - pain, tingling, numbness and temperature sensitivity - in some cases motor nerves are affected, and occasionally, also, the autonomic nervous system. CIPN often follows the first ...
ASCO has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology.1. The guidelines resulted from the efforts of an expert panel, with representation from the fields of medical oncology, community oncology, nursing, pain research, genetics, neurology, pharmacology, patient representation, and guideline methodology. Charles Loprinzi, MD, of the Mayo Clinic, Rochester, Minnesota, and Dawn Hershman, MD, of Columbia University Medical Center, New York, were the panel co-chairs.. The overall incidence of the condition is estimated at close to 40% in patients treated with multiple agents, with reported rates varying according to chemotherapy regimens, duration of exposure, and assessment methods. Regimens associated with higher risk are those including platinum drugs, vinca alkaloids, bortezomib (Velcade), and taxanes.. Clinical Question. The clinical question addressed by ...
Huang, S, et al. (2011) Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J. Biol. Chem.. 2011 Nov 18; 286(46):40002-12. PM ID: ...
To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors.An Expert Panel conducted targeted systematic literature reviews to identify new studies.The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update.The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent ...
Rapid advances have been made in the diagnosis and treatment of neurological disease over the last two decades. Over that period, major developments have also occurred in other fields of medicine, most notably in the management of cancer. Two-thirds of all cancer patients now survive at 5-years post-diagnosis, with over 28 million cancer survivors worldwide.1 As cancer outcomes improve, there has been increased focus on the long-term quality of life in cancer survivors. Not unexpectedly, neurological complications are a prevalent and potentially disabling long-term side effect of cancer treatment. Chemotherapy-induced peripheral neuropathy (CIPN), in particular, is the dose-limiting toxicity of many chemotherapeutic agents, … ...
cansSAR 3D Structure of 6BA5_P | POTENT AND SELECTIVE ANTITUMOR ACTIVITY OF A T-CELL ENGAGING BISPECIFIC ANTIBODY TARGETING A MEMBRANE-PROXIMAL EPITOPE OF ROR1 | 6BA5
The primary objective for this study is to establish if any side effects or toxicity issues occur, that will prevent further clinical development of the autologous cell based immunotherapy ALECSAT in Glioblastoma (GBM) or to establish if there are side effects or toxicity issues, that will suggest that the further clinical development planned, has to change course significantly. It is a primary objective to show safety and tolerability for administration of ALECSAT, thus not meeting this endpoint, may stop further clinical development of ALECSAT.. The secondary objective for this study is to establish if any indications of a positive therapeutic or palliative effect may be observed. As this is a secondary objective, no observed significant positive clinical effect, will not prevent further clinical development or in itself, trigger changes in the further clinical development planned.. The overall endpoint of the study is to develop a new therapeutic approach that may slow down or stop disease ...
TY - JOUR. T1 - erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells. T2 - Association between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair. AU - Arteaga, Carlos L.. AU - Winnier, Angela R.. AU - Hurd, Stephen D.. AU - Stewart, Stanford J.. PY - 1994/7/15. Y1 - 1994/7/15. N2 - The c-erbB-2 (HER-2/neu) protooncogene encodes an Mr 185,000 transmembrane glycoprotein with intrinsic tyrosine kinase activity. Agonistic antibodies against pl85c-erbB-2 enhance the cytotoxic effect of the DNA alkylator, cisplatin, against c-erB-2-overexpressing human carcinoma cells (Hancock et al., Cancer Res., 51: 4575-4580,1991). We have studied the possible association between receptor signal transduction and cispla-tin-mediated cytotoxicity utilizing the SKBR-3 human breast cancer cell line and the anti-pl85 TAb 250 IgGl. TAb 250 induced tyrosine phosphorylation of pl85 and the receptor substrate phospholipase C-yl, as well as rapid association of these ...
TY - JOUR. T1 - Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. AU - Pabla, Navjotsingh. AU - Dong, Guie. AU - Jiang, Man. AU - Huang, Shuang. AU - Kumar, M. Vijay. AU - Messing, Robert O.. AU - Dong, Zheng. PY - 2011/7. Y1 - 2011/7. N2 - Cisplatin is a widely used cancer therapy drug that unfortunately has major side effects in normal tissues, notably nephrotoxicity in kidneys. Despite intensive research, the mechanism of cisplatin-induced nephrotoxicity remains unclear, and renoprotective approaches during cisplatin-based chemotherapy are lacking. Here we have identified PKCδ as a critical regulator of cisplatin nephrotoxicity, which can be effectively targeted for reno-protection during chemotherapy. We showed that early during cisplatin nephrotoxicity, Src interacted with, phosphorylated, and activated PKCδ in mouse kidney lysates. After activation, PKCδ regulated MAPKs, but not p53, to induce renal cell ...
ROCKVILLE, Md., June 2 /PRNewswire-FirstCall/ -- ENMD-2076 Demonstrates Preclinical Antitumor Activity in Colorectal Cancer. Data Published in Clinical...
Cancer is one of the leading causes of death worldwide. According to the WHO, cancer accounted for 7.4 million deaths world wide in 2004. The metallo-compound cisplatin has been used for years as an effective antitumor agent for treating solid tumours such as breast, bladder, lung, oesophageal, and head and neck carcinomas. However, the use of cisplatin as an antitumor agent has been limited because of its association with problems such as lack of selectivity for cancer cells over normal cells, development of resistance to cisplatin treatment, and side effects such as nephrotoxicity. Recent studies on anticancer drugs have focussed on alternative anticancer agents such as gold compounds in both Au(I) and (III) oxidation states, which have shown to be potential anticancer drug agents because of their ability to induce apoptosis in several human cancer cells. Some gold complexes have shown to be able to selectively kill cancer cells over normal cells ...
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone. Chemotherapy-induced peripheral neuropathy commonly occurs in greater than 40% of patients. To improve the peripheral neuropathy, the chemotherapy dosing is often either decreased or discontinued potentially affecting tumor responsiveness, prognosis, and survival.. There is an unmet medical need for treatment of cancer patients with chemotherapy induced neuropathic pain (CINP) and the proposed study will investigate the efficacy and safety of multiple dose levels of tetrodotoxin (TTX) versus placebo in moderate to severe neuropathic pain caused by chemotherapy. ...
Colorectal cancer (CRC) the third leading causes of cancer-related death worldwide with an estimated 639,000 deaths each year. In the United States, CRC is the second leading cause of cancer-related death, resulting in approximately 49,920 deaths in 2009. Despite significant advances in research and development in CRC and gastric cancer, the current response rate for 1st line treatment of mCRC remains ~50% and dramatically decreases for 2nd line therapy. In addition, the five-year survival rate for patients diagnosed with mCRC is approximately 10%. While, molecularly targeted therapies have improved treatment outcomes for patients with cancer, these benefits are modest and in only select patient populations. It is clear that the new chemotherapeutic options and novel drug combinations must be developed to provide benefit for the approximately half of patients that fail to response to current chemotherapeutic options that are available. We hypothesize that combining novel agents that target ...
The present study was designed to determine the effects of artemisinin (ARS) and its derivatives on human ovarian cancer cells, to evaluate their potential as novel chemotherapeutic agents used alone or in combination with a conventional cancer chemotherapeutic agent, and to investigate their underlying mechanisms of action. Human ovarian cancer cells (A2780 and OVCAR-3), and immortalized non-tumourigenic human ovarian surface epithelial cells (IOSE144), were exposed to four ARS compounds for cytotoxicity testing. The in vitro and in vivo antitumour effects and possible underlying mechanisms of action of dihydroartemisinin (DHA), the most effective compound, were further determined in ovarian cancer cells. ...These effects were also observed in in vivo ovarian A2780 and OVCAR-3 xenograft tumour models. In conclusion, ARS derivatives, particularly DHA, exhibit significant anticancer activity against ovarian cancer cells in vitro and in vivo, with minimal toxicity to non-tumourigenic human OSE ...
SHIRLEY, NOV 30TH,2017 - Researchers from the Albert Einstein College of Medicine found a compound that can directly contribute to the suicide of cancer cells for the first time by inducing cell apoptosis, moreover, it will not affect specific compounds in healthy cells of the body. The study results was published in the Journal of Cancer. As a new type of therapy which can directly resist Acute Myeloid Leukemia (AML) cells, it also can help offer effectively supply for other types of cancer cells.. Professor Evripidis Gavathiotis, one of the researchers for this study, claimed that this new targeting compounds they developed were more effective than the current anticancer therapies, which promote cancer cells to self-destruct. Ideally, this new type of compounds will work with other therapies to kill cancer cells more quickly and efficiently but with fewer side effects, while the traditional chemotherapy often causes some side effects to patients.. AML, which accounts for almost a third of ...
Chemotherapy can impact or damage the bodys peripheral nerves. Peripheral nerves carry sensations (or neurological messages) to and from the brain and spine, to control feeling and movement in different parts of the body including arms, legs, hands and feet. They also control the bowel and bladder. Damage to peripheral nerves that is caused by chemotherapy is called
Conventional cytotoxic chemotherapy plays a major role in cancer therapy. Development of intensified regimen improved the outcome of several diseases [45, 46, 49, 66, 67] but is limited by toxic side effects. A major dose-limiting side effect is general haematotoxicity which is routinely treated with growth factors EPO and G-CSF. Different pharmaceutical derivatives of these factors are available, which differ greatly in pharmacokinetic and -dynamic properties. Furthermore, outcome of growth factor treatment depends on many factors such as chemotherapy drugs used, drug doses, growth-factor derivatives and individual risk factors [68, 69]. Due to this variety of variable therapy parameters, identification of optimal growth-factor schedules cannot be performed solely on the basis of clinical trials. We showed in the past that mathematical models of haematopoiesis under chemotherapy can facilitate the development of optimised and individualised growth-factor schedules [6].. Efforts to model ...
Cisplatin is a widely used cancer therapy drug that unfortunately has major side effects in normal tissues, notably nephrotoxicity in kidneys. Despite intensive research, the mechanism of cisplatin-induced nephrotoxicity remains unclear, and renoprotective approaches during cisplatin-based chemotherapy are lacking. Here we have identified PKCδ as a critical regulator of cisplatin nephrotoxicity, which can be effectively targeted for renoprotection during chemotherapy. We showed that early during cisplatin nephrotoxicity, Src interacted with, phosphorylated, and activated PKCδ in mouse kidney lysates. After activation, PKCδ regulated MAPKs, but not p53, to induce renal cell apoptosis. Thus, inhibition of PKCδ pharmacologically or genetically attenuated kidney cell apoptosis and tissue damage, preserving renal function during cisplatin treatment. Conversely, inhibition of PKCδ enhanced cisplatin-induced cell death in multiple cancer cell lines and, remarkably, enhanced the chemotherapeutic ...
Cisplatin is a widely used cancer therapy drug that unfortunately has major side effects in normal tissues, notably nephrotoxicity in kidneys. Despite intensive research, the mechanism of cisplatin-induced nephrotoxicity remains unclear, and renoprotective approaches during cisplatin-based chemotherapy are lacking. Here we have identified PKCδ as a critical regulator of cisplatin nephrotoxicity, which can be effectively targeted for renoprotection during chemotherapy. We showed that early during cisplatin nephrotoxicity, Src interacted with, phosphorylated, and activated PKCδ in mouse kidney lysates. After activation, PKCδ regulated MAPKs, but not p53, to induce renal cell apoptosis. Thus, inhibition of PKCδ pharmacologically or genetically attenuated kidney cell apoptosis and tissue damage, preserving renal function during cisplatin treatment. Conversely, inhibition of PKCδ enhanced cisplatin-induced cell death in multiple cancer cell lines and, remarkably, enhanced the chemotherapeutic ...
rdf:RDF xmlns:dcterms=http://purl.org/dc/terms/ xmlns:dc=http://purl.org/dc/elements/1.1/ xmlns:rdf=http://www.w3.org/1999/02/22-rdf-syntax-ns# xmlns:bibo=http://purl.org/ontology/bibo/ xmlns:dspace=http://digital-repositories.org/ontologies/dspace/0.1.0# xmlns:foaf=http://xmlns.com/foaf/0.1/ xmlns:void=http://rdfs.org/ns/void# xmlns:xsd=http://www.w3.org/2001/XMLSchema# , ,rdf:Description rdf:about=https://kops.uni-konstanz.de/rdf/resource/123456789/20568, ,dcterms:title,lGnRH-III - a Promising Candidate for Anticancer Drug Development,/dcterms:title, ,void:sparqlEndpoint rdf:resource=http://localhost/fuseki/dspace/sparql/, ,dspace:isPartOfCollection rdf:resource=https://kops.uni-konstanz.de/rdf/resource/123456789/52/, ,dc:date rdf:datatype=http://www.w3.org/2001/XMLSchema#dateTime,2013-03-13T13:52:23Z,/dc:date, ,dc:creator,Mező, Gabor,/dc:creator, ,dc:rights,deposit-license,/dc:rights, ,dcterms:bibliographicCitation,Protein Peptide Letters ; 20 (2013), 4. - S. ...
Treatment of multifunctional diseases such as cancer typically cannot be achieved by therapeutic agents that inhibit a single target.1 Single agent therapeutics often lead to development of drug resistance as well as limited accessibility of drug to tumour tissue due to intra-tumour heterogeneity.2 Moreover, in order to achieve therapeutically relevant concentrations within the tumour, high systemic doses of chemotherapy agents need to be administered, often resulting in severe toxic side effects.3 This is the case with drugs such as cisplatin and other platinum derivative drugs that are widely used in the treatment of ovarian cancer and head and neck squamous cell carcinoma (HNSCC).4,5 The primary mechanism of action of cisplatin is through DNA damage.6 However, several cellular pathways are activated by cisplatin exposure, including DNA repair pathways that remove the damage and result in the emergence of drug resistance.7 It has been shown that a combination of multiple anticancer drugs can ...
Multidrug resistance is a major barrier against successful chemotherapy, and this has been shown in vitro to be often caused by ATP-binding cassette (ABC) transporters. These transporters are frequently overexpressed in human cancers and confer an adverse prognosis in many common malignancies. The genetic factors, however, that initiate their expression in cancer are largely unknown. Here we report that the major multidrug transporter ABCG2 (BCRP/MXR) is directly and specifically activated by the transcription factor E2F1-a factor perturbed in the majority of human cancers. E2F1 regulates ABCG2 expression in multiple cell systems, and, importantly, we have identified a significant correlation between elevated E2F1 and ABCG2 expression in human lung cancers. We show that E2F1 causes chemotherapeutic drug efflux both in vitro and in vivo via ABCG2. Furthermore, the E2F1-ABCG2 axis suppresses chemotherapy-induced cell death that can be restored by the inhibition of ABCG2. These findings therefore ...
The establishment of new treatment options for chemo- and radiation-resistant NETs is essential because of the inefficacy of conventional chemotherapy. Medicinal herbs have come increasingly into the spotlight as complementary medicines. In the present study, we provide a first report of the antitumor activity of plant extracts from Christia vespertilionis, in which the ethylacetate fraction CV-45 showed significant antiproliferative and pro-apoptotic effects in MTC-SK as well as in KRJ-I cells.. It is known that many chemotherapeutic agents are able to induce apoptosis in cancer cells, as with sorafenib or 5-fluorouracil for human hepatoma cells (18,19). One goal in the establishment of new therapies against NETs is to define substances that have the ability to trigger anticancer effects and to induce apoptosis specifically in tumor cells, but not in normal cells.. In the human fibroblasts (HF-SAR) tested, the same concentration of CV-45 (10 μg/ml) as used for tumor cells did not inhibit ...
Paclitaxel is a standard chemotherapeutic agent for ovarian cancer. Resistance of ovarian cancer cells to the drug has been a major obstacle in clinical practice. Thus, alternative approaches are needed to conquer the resistance. PEA-15 (phosphoprotein enriched in astrocytes-15 kDa) regulates cell proliferation and apoptosis. It is phosphorylated at S104 and S116 by Akt, PKC and CaMKII. PEA-15s functions are phosphorylation dependent. Although PEA-15 is known to mediate chemoresistance in breast cancer, the effect of PEA-15 phosphorylation status on chemosensitivity remains unknown. We hypothesized that phospho-PEA-15 (pPEA-15) enhances sensitivity of ovarian cancer cells to paclitaxel. To test our hypothesis, we silenced PEA-15 expression in HEY and OVTOKO cells using siRNA and observed a 14% reduction in apoptosis after paclitaxel exposure. To further determine if PEA-15 phosphorylation contributes to chemosensitivity, we generated SKOV3.ip1-vector (control), SKOV3.ip1-AA (AA, ...
The natural product (-)-dictyostatin is a microtubule stabilizing agent that potently inhibits the growth of human cancer cells including paclitaxel-resistant clones. Extensive structure-activity relationship studies have revealed several regions of the molecule that could be altered without loss of activity. The most potent synthetic dictyostatin analog described to date, 6-epi-dictyostatin, has in vivo antitumor activity against human breast cancer xenografts superior to paclitaxel. Despite their encouraging preclinical activities, the complex chemical structure of the dictyostatins presents a major obstacle in their development into novel antineoplastic therapies. We recently reported a streamlined synthesis of 16-desmethyl-25,26 dihydrodictyostatins and found several agents that compared with 6-epi-dictyostatin retained nanomolar activity in cellular microtubule bundling assays but showed cross-resistance to paclitaxel in cells with mutations in beta-tubulin. Extending these studies, we ...
The development of new anti-cancer treatments with greater efficacy and fewer side effects remains a significant challenge of modern scientific and medical research. Curcumin, a natural polyphenol found in the dietary spice turmeric, has been demonstrated to inhibit cancer cell survival and proliferation, and to in Chemistry for Medicine: Special Collection for RSC Advances Bioconvergence for food function
Abstract Purpose Subsequent to chemotherapy treatment, breast cancer patients often report a decline in cognitive functioning that can adversely impact many aspects of their lives. Evidence has mounted in recent years indicating that a portion of breast cancer survivors who have undergone chemotherapy display reduced performance on objective measures of cognitive functioning relative to comparison groups. Neurophysiological support for chemotherapy-related cognitive impairment has been accumulating due to an increase in neuroimaging studies in this field; however, longitudinal studies are limited and have not examined the relationship between structural grey matter alterations and neuropsychological performance. The aim of this study was to extend the cancer-cognition literature by investigating the association between grey matter attenuation and objectively measured cognitive functioning in chemotherapy-treated breast cancer patients. Methods Female breast cancer patients (n = 19) underwent ...
The mechanisms underlying the proapoptotic effect of the chemotherapeutic agent, cisplatin, are undefined largely. MAPK-dependent system. Cisplatin treatment coupled with particular inhibitors to each MAPK pathway (c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38) led to reduced ATF3 induction on the proteins level. MAPK pathway inhibition resulted in reduced ATF3 messenger RNA appearance and decreased cytotoxic ramifications of cisplatin as assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay. In A549 lung carcinoma cells, concentrating on ATF3 with specific little hairpin RNA attenuated the cytotoxic ramifications of cisplatin also. Likewise, ATF3-/- murine embryonic fibroblasts (MEFs) had been been shown to be much less delicate to cisplatin-induced cytotoxicity weighed against ATF3+/+ MEFs. This research recognizes cisplatin being a MAPK pathway-dependent inducer of ATF3, whose expression influences cisplatins cytotoxic ...
The antiangiogenic effects need to be fine-tuned and adapted over time to obtain the best antitumor response possible because suboptimal antiangiogenic therapy might, in some cases, lead to potentially more aggressive tumor progression (23). Combined with conventional cytotoxic drugs, the extent of the antiangiogenic activity might determine whether the combination is synergistic, for instance, by transient normalization of the tumor vasculature resulting in temporarily better oxygenation and drug deposition (24), otherwise, the combination could be antagonistic. A further layer of complexity derives from the finding that most conventional, and many targeted antitumor agents, exert accidental antiangiogenic effects (25). Indeed, if given in a metronomic fashion (i.e., administered frequently in comparatively low doses over prolonged periods with no prolonged breaks), traditional cytotoxic drugs might act primarily via antiangiogenic mechanisms that are accompanied by only low-grade toxicity ...
Sulfonamides are the first effective chemotherapeutic agents used for several years to cure or prevent systemic bacterial infections. In addition, this agents showed anti-carbonic anhydrase and cause cell cycle perturbation in the G1 phase, disruption of microtubule assembly, suppression of the transcription activator Nf-Y, angiogenesis and matrix metalloproteinase (MMP). In recent years, novel synthesized sulfonamides have been introduced as antitumor, antiviral and anti-inflammatory agents. In this paper, the cytotoxic effects of 8 synthesized sulfonamides were investigated by MTT assay on HeLa, MDA-MD-468 and MCF-7 cancer cell lines. Human cancer cells were cultured and passaged in RPMI-1640 medium. Cells incubated in 96-well plates in a concentration of 1 × 105 cells/mL for 24 h, and then logarithmic concentrations (0.1 µm, 1 µm, 10 µm, 100 µm, 1mM) of each drug were prepared, added to the plates and incubated for 72 h. Cell survival was then determined using ELISA plate reader in 540 nm
TY - JOUR. T1 - Continuing challenges and current issues in acute lymphoblastic leukemia. AU - Kansagra, Ankit. AU - Dahiya, Saurabh. AU - Litzow, Mark. PY - 2017/6/12. Y1 - 2017/6/12. N2 - Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL) has resulted into high cure rates for pediatric patients, however outcomes for adult patients remain suboptimal. The 5-year overall survival is only 30-40% in adults and elderly patients with ALL compared to 90% in children. We have seen major advances in our understanding and management of ALL related to identification of new cytogenetic and molecular abnormalities and development of novel targeted agents for the treatment of ALL. The addition of tyrosine kinase inhibitors, monoclonal antibodies and novel immune therapies (e.g. bispecific T cell engager [BiTE] and chimeric antigen receptor [CAR] T cells) has resulted in improved outcomes. These new developments are changing the treatment paradigm of adults ALL from a one ...
Multi-drug resistance is the biggest threat to long-term survival of cancer patients. Despite treatment, some tumor cells survive chemotherapy and become resistant to the drugs, causing follow-up treatments to fail. These drug-resistant tumors become untreatable and continue to flourish, ultimately killing the patient. Multi-drug resistance proteins expressed by tumor cells are a major source of resistance to conventional chemotherapeutic drugs. Small interfering RNAs (siRNAs) can silence these messenger RNAs that make multi-drug resistance proteins and EnGeneIC has discovered that EDVs can effectively load up to 10,000 copies of siRNA and deliver them directly to cancer cells. This process silences the respective messenger RNAs and makes the tumor cells sensitive to chemotherapeutic drugs which are subsequently delivered via the EDVs to eradicate the formerly drug resistant tumor. EnGeneIC has demonstrated in mouse studies carrying human drug resistant tumors and the data has been published in ...
Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. This review summarizes the results of prospective clinical trials of several categories of systemic therapy, with emphasis on the more promising results from recent trials of biologically targeted therapeutic agents in HCC.
Abstract Background Cisplatin is a platinum-based chemotherapeutic that damages genomic DNA leading to cell death. It also damages mitochondrial DNA and...
This thesis describes bioanalysis of small and large molecules in biological matrices and includes screening of illegal drugs in urine with high resolution mass spectrometer, bioanalysis of MTH1 inhibitors in mice plasma and quantification of proteins in plasma and cell lysates.. Screening of illegal drugs was based on high resolving power mass spectrometer (QTOF) and the results were compared to immunoassays. For the study, the nine most commonly abused drugs were selected for screening of a large number of authentic urine samples. Evaluation of the screening results showed that the QTOF generated a low rate of false positive and false negative results and can be used as an alternative or a complementary to immunoassays.. In another study, a bioanalytical method for the two new anticancer targets TH588 and TH287 was developed and validated. The compounds inhibit the MTH1 protein that is required for cancer cell survival. To study the pharmacokinetic properties of the substances, a bioanalytical ...
TY - JOUR. T1 - Synthesis and evaluation of Taxol-folic acid conjugates as targeted antineoplastics. AU - Lee, Jae Wook. AU - Lu, June Y.. AU - Low, Philip. AU - Fuchs, P. L.. PY - 2002/5/8. Y1 - 2002/5/8. N2 - A series of Taxol derivatives tethered at C2′ and C-7 to glutamate and folate have been synthesized for evaluation as prodrugs which release Taxol via hydrolytic lability of their α-alkoxy and α-amino esters. The half-time for hydrolysis of these materials was determined in pH 7 and pH 5 buffer. The in vitro cytotoxicity has been assessed in cell culture against A-549 lung cancer, MCF-7 breast cancer, and HT-29 colon cancer. Selected agents were further screened for folate binding and competitive binding with free folic acid. One agent (54), further evaluated in animal studies was found to increase the lifespan in mice, but was less effective than Taxol itself.. AB - A series of Taxol derivatives tethered at C2′ and C-7 to glutamate and folate have been synthesized for evaluation as ...
Chemotherapy is one of the most important therapeutic options used to treat human cancers, either alone or in combination with radiation therapy and surgery. Recent studies have indicated that intra-tumoural heterogeneity has a significant role in driving resistance to chemotherapy in many human malignancies. Multiple factors including the internal cell-cycle dynamics and the external microenvironement contribute to the intra-tumoural heterogeneity. In this paper we present a hybrid, multiscale, individual-based mathematical model, incorporating internal cell-cycle dynamics and changes in oxygen concentration, to study the effects of delivery of several different chemotherapeutic drugs on the heterogeneous subpopulations of cancer cells with varying cell-cycle dynamics. The computational simulation results from the multiscale model are in good agreement with available experimental data and support the hypothesis that slow-cycling sub-populations of tumour cells within a growing tumour mass can ...
Chemotherapy is one of the most important therapeutic options used to treat human cancers, either alone or in combination with radiation therapy and surgery. Recent studies have indicated that intra-tumoural heterogeneity has a significant role in driving resistance to chemotherapy in many human malignancies. Multiple factors including the internal cell-cycle dynamics and the external microenvironement contribute to the intra-tumoural heterogeneity. In this paper we present a hybrid, multiscale, individual-based mathematical model, incorporating internal cell-cycle dynamics and changes in oxygen concentration, to study the effects of delivery of several different chemotherapeutic drugs on the heterogeneous subpopulations of cancer cells with varying cell-cycle dynamics. The computational simulation results from the multiscale model are in good agreement with available experimental data and support the hypothesis that slow-cycling sub-populations of tumour cells within a growing tumour mass can ...
Cancer research is an area of biology where growth curve analysis plays an important role. In many types of cancer, the rate at which tumors shrink following chemotherapy is related to the rate of tumor growth before treatment. Tumors that grow rapidly are generally more sensitive to the toxic effects that conventional anticancer drugs have on the cancer cells. Many conventional anticancer drugs (for example, 5-Fluorouracil) interfere with DNA replication and can cause the death of cells that attempt to replicate their DNA and divide. A rapidly growing tumor will have more actively dividing cells and more cell death upon exposure to such anticancer drugs. ...
DESCRIPTION (provided by applicant): We will conduct Phase I clinical trials of new anticancer agents or combinations of anticancer agents to characterize drug toxicity, determine the maximum tolerated dose, evaluate the pharmacokinetics, perform pharmacogenetic analysis, and relating clinical endpoints to pharmacokinetics, pharmacogenetics, and/or biologic endpoints. A major focus of this proposal is the study agents that interact with novel targets such as signal transduction pathways, cell cycle checkpoint components, DNA repair pathways and apoptosis regulators, either alone or in combination with standard chemotherapy. The endpoints for the evaluation of such treatments will be clinical effect (toxicity and antineoplasti response) as well as alterations in biochemical pathways affected in preclinical model systems. The specific aims of these studies are: to determine as efficiently as compatible with patient safety the appropriate dose of new anticancer agents selected by the National ...
Purpose: Ridaforolimus (MK-8669, AP23573) is a potent and selective mTOR inhibitor. Preclinically, ridaforolimus displays antiproliferative activity against a variety of human tumors in vitro and tumor xenograft models in vivo, with additive or synergistic activity when combined with other anticancer agents. Anti-tumor activity has been confirmed in adults. This phase I study determined the safety, pharmacological, biologic, and toxicity profiles of ridaforolimus in pediatric patients with refractory malignancies. Experimental Design: Eligible children ages 1-18 years with advanced solid tumors were enrolled in a 3+3 dose escalation design, to determine the safety, tolerability, and maximum tolerated dose (MTD)/dose limiting toxicity (DLT) of ridaforolimus. Toxicities, pharmacokinetics and pharmacodynamics were characterized. Results: Fifteen patients were treated. No dose-limiting toxicity was observed at any dose level tested; therefore, an MTD was not identified. Most adverse events were mild ...
Amgen, a drug company, stopped studies of a pancreatic cancer drug just shy of the studys end due to results that did not live up to expected standards.. The drug was not found to affect patients longevity, and the study was stopped during the final step of the human trial process. According to Bloomberg.com, the addition of ganitumab to the pancreatic cancer drug, gemcitabine, is meant to target the type 1 insulin growth factor receptor. The other name of the pancreatic cancer drug is AMG 479.. The main goal of this ingredient in the pancreatic cancer drug is to regulate cell growth.. Previous test trials for colorectal and small-cell lung cancer are currently being reviewed, as they too involved the pancreatic cancer drug.. Sean Harper, executive vice president of research and development at Amgen, said, These disappointing results underscore the difficulty of treating pancreatic cancer, which remains a major unmet medical need.. According to Reuters, while the pancreatic cancer drug ...
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting and disabling side effect of taxane anticancer agents. We prospectively evaluated the efficacy of cryotherapy for CIPN prevention. Methods: Breast cancer patients treated weekly with paclitaxel (80 mg/m2 for one hour) wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion. Symptoms on the treated sides were compared with those on the untreated (nondominant) sides. The primary end point was CIPN incidence assessed by changes in tactile sensitivity from pretreatment baseline in a monofilament test at a cumulative dose of 960 mg/m2. We also assessed thermosensory deficits, subjective symptoms (Patient Neuropathy Questionnaire [PNQ]), manipulative dexterity, and the time to events and hazard ratio by PNQ. All statistical tests were two-sided. Results: Among the 40 patients, four did not reach the cumulative dose (due to the occurrence of pneumonia, severe ...
Great strides are being made in understanding the signaling pathways involved in initiation and growth of cancers, as well as their abilities to evade treatment. Some of this research is being driven by the development of new chemotherapeutics. Accordingly, there is a broadening spectrum of potential drugs in various stages of clinical trials that can be used to treat this highly invasive disease. The continued development of new chemotherapeutic agents and the identification of novel cellular targets are imperative for the successful treatment of cancer, as well as to gain a more complete understanding of how cells work. Such efforts will bring us closer to the goal of personalizing medicine by targeting specific weaknesses in certain types of cancer. The overarching theme of the work contained herein has been the identification of potential chemotherapeutic agents. Multiple strategies have been employed, from assessment of a compound selective for white blood cell cancers to analysis of ...
"Antineoplastic agents. 47. Structure of an antineoplastic agent from Streptomyces griseoluteus". Journal of the American ...
"Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine ... "Antineoplastic agents. 257. Isolation and structure of spongistatin 1". Journal of Organic Chemistry. 58 (6): 1302-1304. doi: ...
The bulbs of N. poeticus contain the antineoplastic agent narciclasine. This usage is also found in later Arabian, North ... Pettit, GR; Cragg, GM; Singh, SB; Duke, JA; Doubek, DL (1990). "Antineoplastic agents, 162. Zephyranthes candida". Journal of ... "Antineoplastic Agents. 587. Isolation and Structure of 3-Epipancratistatin from Narcissus cv. Ice Follies". Journal of Natural ... as Potential Anticancer Agents". Journal of Medicinal Chemistry. 52 (4): 1100-1114. doi:10.1021/jm8013585. PMID 19199649. ...
Pettit GR, Xu JP, Chapuis JC, Pettit RK, Tackett LP, Doubek DL, Hooper JN, Schmidt JM (2004). "Antineoplastic agents. 520. ...
Pettit, G. R.; Gaddamidi, V.; Goswami, A.; Cragg, G. M. (1984). "Antineoplastic agents,99. Amaryllis beladonna". Journal of ...
Certain antineoplastic agents, bryostatins 4 and 5, have been extracted from Aplidium californicum and are being evaluated. ... Pettit GR, Leet JE, Herald CL, Kamano Y, Doubek DL (1986). "Antineoplastic agents, 116. An evaluation of the marine ascidian ...
CS1 maint: discouraged parameter (link) Pettit GR, Cragg GM, Singh SB (May-June 1987). "Antineoplastic agents, 122. ...
"Antineoplastic Agents, Hormonal". Medical Subject Headings. U.S. National Library of Medicine. 2009. Retrieved 11 November 2010 ...
ISBN 978-3-642-99941-3. Alan C. Sartorelli; David G. Johns (27 November 2013). Antineoplastic and Immunosuppressive Agents. ... Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Halogenated ... Carpenter JT (1988). "Progestational agents in the treatment of breast cancer". Cancer Treat. Res. Cancer Treatment and ...
Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Nathanson ... 549-. ISBN 978-3-642-30725-6. The first sex steroid used as pharmacological agent was Progynon, first sold by Schering AG in ...
Sartorelli AC, Johns DG (27 November 2013). Antineoplastic and Immunosuppressive Agents. Springer Science & Business Media. pp ...
31-. ISBN 978-1-4613-2157-6. Sartorelli AC, Johns DG (27 November 2013). Antineoplastic and Immunosuppressive Agents. Springer ...
83-. ISBN 978-1-4832-7299-3. Alan C. Sartorelli; David G. Johns (27 November 2013). Antineoplastic and Immunosuppressive Agents ...
Sartorelli, Alan C.; Johns, David G. (27 November 2013). Antineoplastic and Immunosuppressive Agents. Springer Science & ... Anthramycin is an active anti-tumor agent and antibiotic. It works by inhibiting the synthesis of RNA and DNA of carcinoma ...
Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Crowley, ... Geller J, Fruchtman B, Newman H, Roberts T, Silva R (February 1967). "Effect of progestational agents on carcinoma of the ... Hall NR (June 2011). "What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?". Obstetrics ... In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding ...
Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. ...
Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Oxylone ... ISBN 978-3-88763-075-1. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and ...
Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Council on ... However, androstanolone is nonetheless described as a very poor anabolic agent. This is attributed to its high affinity as a ... von Deutsch DA, Abukhalaf IK, Lapu-Bula R (15 October 2003). "Anabolic Doping Agents". In Mozayani A, Raymon L (eds.). Handbook ... 63-. ISBN 978-3-88763-075-1. Morton I, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and ...
ISBN 978-0-323-13916-8. Alan C. Sartorelli; David G. Johns (27 November 2013). Antineoplastic and Immunosuppressive Agents. ...
Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. v t e v t e ...
31-. ISBN 978-1-4613-2157-6. Alan C. Sartorelli; David G. Johns (27 November 2013). Antineoplastic and Immunosuppressive Agents ... I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer ...
It has the role of antineoplastic agent, which means it can inhibit or prevent the neoplasms' proliferation. It is also the ... "antineoplastic agent (CHEBI:35610)". www.ebi.ac.uk. Retrieved 2019-10-26. "1-deoxysphinganine". Avanti Polar Lipids. Retrieved ...
Antineoplastic and Immunosuppressive Agents. Springer Science & Business Media. pp. 181-. ISBN 978-3-642-65806-8. Heinrich Kahr ...
Available agents[edit]. Main article: List of antineoplastic agents. There is an extensive list of antineoplastic agents. ... Alkylating agents[edit]. Main article: Alkylating antineoplastic agent. Alkylating agents are the oldest group of ... The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs.[ ... Antineoplastic Agents in Encyclopedia of Molecular Pharmacology, 2nd Edition, Volume 1. Eds. Offermanns S and Rosenthal W. ...
It is an antineoplastic agent. It exerts its effect by acting as a suicide inhibitor of the enzyme O6-alkylguanine-DNA ... O6-BG was used clinically in combination with the alkylating agent temozolomide for glioblastoma, however the combination was ...
Milne GW (1 July 2000). Ashgate Handbook of Antineoplastic Agents. Wiley. p. 5. ISBN 978-0-566-08382-2. Tripathi KD (30 ... List of hormonal cytostatic antineoplastic agents List of estrogen esters § Estradiol esters NCI Thesaurus. "Alestramustine". ... is a cytostatic antineoplastic agent which was never marketed. It is the L-alanine ester of estramustine, which is a ...
... an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to ...
... is an antineoplastic agent. Chemically, it is a pegylated F(ab')2 fragment of a monoclonal antibody. ...
Antineoplastic and Immunosuppressive Agents part 2. Springer Science & Business Media. ISBN 978-3-642-65806-8. Hatano, K. (2003 ...
Targeted cancer therapy / antineoplastic agents (L01). CI monoclonal antibodies ("-mab"). Receptor tyrosine kinase. *ErbB: HER1 ... ocrelizumab, humanized (90%-95% human) B cell-depleting agent.. *ofatumumab (HuMax-CD20) a fully human B cell-depleting agent.[ ... The use of rituximab has not been proven to be efficacious in this setting and like all depleting agents, carries with it the ...
Targeted cancer therapy / antineoplastic agents (L01). CI monoclonal antibodies ("-mab"). Receptor tyrosine kinase. *ErbB: HER1 ... BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following BIBW 2992 Monotherapy in ...
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.. *v ... List of investigational hormonal agents § Estrogenics. References[edit]. *^ Gauthier, S; Cloutier, J; Dory, YL; Favre, A; ...
... followed by death allowing for evaluation of novel cytoprotective agents. Potential tissue reparative agents can be evaluated ... Bleomycin is an antineoplastic antibiotic drug isolated in 1966 from the actinomycete Streptomyces verticillus. Bleomycin forms ... Other inhaled agents may be directly toxic (e.g. cyanide, carbon monoxide), or cause harm simply by displacing oxygen and ... These agents are less likely to produce early warning signs (phosgene in low concentrations has a pleasant odor), are more ...
The agents nafarelin and triptorelin are agonists with single substitutions at position 6. ... Cryptorchidism; Delayed puberty; Diagnostic agent (pituitary disorders); Hypogonadotropic hypogonadism; Veterinary medicine ( ... endometrial thinning agent); Uterine fibroids; Uterine hemorrhage. Implant. 1989. 400,000 ...
... increases the number of cancer cells killed by antineoplastic drugs.[80] ... cannabisin B possesses considerable antiproliferative activity and that it may be utilised as a promising chemopreventive agent ...
Intracellular chemotherapeutic agents / antineoplastic agents (L01). SPs/MIs. (M phase). Block microtubule assembly. *Vinca ...
Intracellular chemotherapeutic agents / antineoplastic agents (L01). SPs/MIs. (M phase). Block microtubule assembly. *Vinca ... This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.. *v ...
Cannabinoids are used in patients with cachexia, cytotoxic nausea, and vomiting, or who are unresponsive to other agents. These ...
Targeted cancer therapy / antineoplastic agents (L01). CI monoclonal antibodies ("-mab"). Receptor tyrosine kinase. *ErbB: HER1 ...
Psychotropic agents[edit]. Other psychotropic analgesic agents include ketamine (an NMDA receptor antagonist), clonidine and ... Unselective agents Aceclofenac. Comes in betadex salt and free acid forms; practically insoluble in water, soluble in many ... Other agents directly potentiate the effects of analgesics, such as using hydroxyzine, promethazine, carisoprodol, or ... When choosing analgesics, the severity and response to other medication determines the choice of agent; the World Health ...
It may be used as a nasal/sinus decongestant, as a stimulant,[119] or as a wakefulness-promoting agent.[120] ... Tashkin, D. P. (1 March 2001). "Airway effects of marijuana, cocaine, and other inhaled illicit agents". Current Opinion in ... and anorectic agent.[112] It is commonly used in prescription and over-the-counter cough and cold preparations. In veterinary ... "Phenylisopropylamine stimulants: amphetamine-related agents". In Lemke TL, Williams DA, Roche VF, Zito W (eds.). Foye's ...
Intracellular chemotherapeutic agents / antineoplastic agents (L01). SPs/MIs. (M phase). Block microtubule assembly. *Vinca ... Romidepsin, also known as Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell ...
List of agents[edit]. Adrenaline releasing agents[edit]. Main article: Norepinephrine releasing agent ... 3 List of agents *3.1 Adrenaline releasing agents *3.1.1 Common or widely marketed ... since these agents lose effectiveness after a few days. ...
This mechanism of toxicity is relevant to the function of anti-cancer drugs in the form of alkylating antineoplastic agents. ... Nucleophilic alkylating agentsEdit. Nucleophilic alkylating agents deliver the equivalent of an alkyl anion (carbanion). The ... Electrophilic alkylating agentsEdit. Electrophilic alkylating agents deliver the equivalent of an alkyl cation. Alkyl halides ... Alkylation is accomplished with the class of drugs called alkylating antineoplastic agents. ...
Cragg, Gordon M.; Newman, David J. (2005). "Plants as a source of anti-cancer agents". Journal of Ethnopharmacology. 100 (1-2 ... in combination with other antineoplastic drugs.[3] In Europe, it is also approved for the treatment of Hodgkin's lymphoma, ... Teniposide, when used with other chemotherapeutic agents for the treatment of ALL, results in severe bone marrow suppression. ...
Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents) as part of a ... Hormones are important agents in sex-related cancers, such as cancer of the breast, endometrium, prostate, ovary and testis and ... Physical agents. Some substances cause cancer primarily through their physical, rather than chemical, effects.[63] A prominent ... Agents (e.g. viruses) and events (e.g. mutations) that cause or facilitate genetic changes in cells destined to become cancer. ...
Intracellular chemotherapeutic agents / antineoplastic agents (L01). SPs/MIs. (M phase). Block microtubule assembly. *Vinca ... Additionally, these agent can be administered orally, a significant advantage. Chlorambucil was first synthesized by Everett et ... In the 1950s, aromatic mustards like chlorambucil were introduced as less toxic alkylating agents than the aliphatic nitrogen ... Like many alkylating agents, chlorambucil has been associated with the development of other forms of cancer. ...
One class of these agents are bryostatin-like compounds, under investigation as anti-cancer therapy.[citation needed] ... For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs, the numbers ... Artemisinin, an antimalarial agent from sweet wormtree Artemisia annua, used in Chinese medicine since 200BC is one drug used ... The elucidation of the chemical structure is critical to avoid the re-discovery of a chemical agent that is already known for ...
Alkylating antineoplastic agents (e.g. mechlorethamine). *Other alkylating agents (e.g. dimethyl sulfate) ... Genotoxins include chemical agents like N-nitroso-N-methylurea (NMU) or non-chemical agents such as ultraviolet light and ... Occupational carcinogens are agents that pose a risk of cancer in several specific work-locations:. Carcinogen. Associated ... Group 4: the agent (mixture) is probably not carcinogenic to humans.. Globally Harmonized SystemEdit. The Globally Harmonized ...
Intracellular chemotherapeutic agents / antineoplastic agents (L01). SPs/MIs. (M phase). Block microtubule assembly. *Vinca ... Utilizing ribociclib in combination with other agents has been shown to reduce the development of resistance to these agents.[3 ...
Intracellular chemotherapeutic agents / antineoplastic agents (L01). SPs/MIs. (M phase). Block microtubule assembly. *Vinca ... As a purine analog, it is a synthetic chemotherapy agent that targets lymphocytes and selectively suppresses the immune system ... It used, often in combination with other cytotoxic agents, to treat various kinds of histiocytosis, including Erdheim-Chester ...
"Dermatotherapeutic Agents". Ullmann's Encyclopedia of Industrial Chemistry (7th ed.). 2007. doi:10.1002/14356007.a08_301.pub2. ... Kyriakidis I, Tragiannidis A, Munchen S, Groll AH (February 2017). "Clinical hepatotoxicity associated with antifungal agents ... "The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents ... "Current and emerging azole antifungal agents". Clinical Microbiology Reviews. 12 (1): 40-79. PMC 88906. PMID 9880474 ...
Intracellular chemotherapeutic agents / antineoplastic agents (L01). SPs/MIs. (M phase). Block microtubule assembly. *Vinca ... Richards, A. D.; Rodgers, A. (2007). "Synthetic metallomolecules as agents for the control of DNA structure". Chemical Society ... Development and Action of Anticancer Agents. 18. Berlin: de Gruyter GmbH. pp. 387-435. doi:10.1515/9783110470734-020.. ...
8 Immunomodulators and antineoplastics *8.1 Immunomodulators for non-malignant disease. *8.2 Antineoplastics and supportive ... Lipid-lowering agents[edit]. *Simvastatin[note 72]. Dermatological medicines (topical)[edit]. Antifungal medicines[edit]. * ... Immunomodulators and antineoplastics[edit]. Immunomodulators for non-malignant disease[edit]. *Adalimumabα[note 59] ... Diagnostic agents[edit]. *Tuberculin, purified protein derivative (PPD). Sera and immunoglobulins[edit]. *Antivenom ...
Within the class of medications, there is no clear evidence that one agent works better than another.[1][2] ... In British Columbia, Canada the cost of the PPIs varies significantly from 0.20 CAD to 2.38 CAD per dose while all agents in ... The cost between different agents varies significantly.[1] ...
The term "calcium-sparing diuretic" is sometimes used to identify agents that result in a relatively low rate of excretion of ... Alternatively, an antidiuretic, such as vasopressin (antidiuretic hormone), is an agent or drug which reduces the excretion of ... Diuretics increase the urine volume and dilute doping agents and their metabolites. Another use is to rapidly lose weight to ... "The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and ...
"Antineoplastic Agents, Hormonal". Medical Subject Headings. U.S. National Library of Medicine. 2009. Retrieved 11 November 2010 ...
The adverse health effects associated with antineoplastic agents (cancer chemotherapy drugs, cytotoxic drugs) in cancer ... In addition to acute or short-term effects related to treatment with antineoplastic agents, there are a number of long-term or ... The very nature of antineoplastic agents make them harmful to healthy cells and tissues as well as the cancerous cells. For ... The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs. ...
Antineoplastic agents. Class Summary. Although the optimal chemotherapeutic regimen for glioblastoma is not yet defined, ... First-line agent in patients with partial and tonic-clonic seizures. Serum levels should be checked and should be approximately ... Oral alkylating agent converted to MTIC at physiologic pH; 100% bioavailable; approximately 35% crosses the blood-brain barrier ... These agents reduce edema around the tumor, frequently leading to symptomatic and objective improvement. ...
Antineoplastic Agent, Alkylating Agent. Class Summary. These agents inhibit cell growth and proliferation. ... Oral alkylating agent converted to MTIC at physiologic pH; 100% bioavailable; approximately 35% crosses the blood-brain barrier ... These agents prevent seizure recurrence and terminate clinical and electrical seizure activity. ... which can interfere with antineoplastic therapy. Steroid therapy, usually combined with a gastroprotectant, is initiated for ...
... Brandi Anders,1 Alexandra Shillingburg,2 and Michael Newton2,3 ... A median of 8 days elapsed between when the prescription for a first-time fill of a new oral antineoplastic agent was written ... Patients 18 years of age and older, who received a new prescription (first-time fill) for an oral antineoplastic agent, were ... The study was undertaken to determine the length of time between when a prescription for an oral antineoplastic agent is ...
This is a list of antineoplastic agents used to treat cancer. Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). ...
Neoplastic Agents Market Emerging Trends ,, Leading Players are Roche, Novartis, Celgene - published on openPR.com ... This study provides Anti - Neoplastic Agents sales, revenue, and market share for each player covered in this report for a ... The Anti - Neoplastic Agents Market report provides a detailed analysis of the global market size, regional and country-level ... Anti - Neoplastic Agents Market Emerging Trends ,, Leading Players are Roche, Novartis, Celgene. 03-31-2020 06:48 AM CET , ...
E. Syrigou, N. Makrilia, I. Koti, M. W. Saif, and K. N. Syrigos, "Hypersensitivity reactions to antineoplastic agents: an ... E. Syrigou, K. Syrigos, and M. W. Saif, "Hypersensitivity reactions to oxaliplatin and other antineoplastic agents," Current ... Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review. Nektaria Makrilia,1 Ekaterini ... Substituting with a Different Platinum Agent. Substituting one platinum agent with another without additional desensitization ...
Cell-cycle nonspecific antineoplastic agents (CCNS) refer to a class of pharmaceuticals that act as antitumor agents at all or ... Alkylating antineoplastic agent and anthracyclins are two examples. "Chemotherapy: The Basics". OncoLink. Archived from the ... "Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product". Cancer ...
Antineoplastic Agents 237 Neoplasms 204 drug therapy 195 Cancer 132 Chemotherapy more ... 124 Antineoplastic agents 51 ... Showing 1 - 20 results of 314 for search Antineoplastic Agents therapeutic use. Skip to content Antineoplastic Agents therapeutic use., query time: 0.59s ...
that is in a class of medications called antineoplastic agents. It works by slowing or stopping the growth ... ... is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a ... ... Mitotane is in a class of medications called antineoplastic agents. It works by slowing growth or reducing the ... ... Bortezomib is in a class of medications called antineoplastic agents. It works by killing cancer cells. ...
Alkylating agents, antimetabolites, and antibiotics have all been considered inhibitors of wound healing. Ac... more ... Many antineoplastic and immunosuppressive agents have been thought to retard wound healing. ... Many antineoplastic and immunosuppressive agents have been thought to retard wound healing. Alkylating agents, antimetabolites ... However, the use of immunosuppressive or antineoplastic agents may predispose the patient to an even greater risk of infection ...
Hints: Click on a [map] link to show a map of that region. Click on a [studies] link to search within your current results for studies in that region. Use the back button to return to this list and try another region. Studies with no locations are not included in the counts or on the map. Studies with multiple locations are included in each region containing locations ...
Find clinical trials studying antineoplastic agent combination sm-88. ... The clinical trials on this list are studying Antineoplastic Agent Combination SM-88. All trials on the list are supported by ...
Antineoplastic Agents, Phytogenic. Accession Number. DBCAT000717. Description. Agents obtained from higher plants that have ... A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary ... A cytotoxic agent used for the removal of soft genital (venereal) warts (condylomata acuminata).. ... A topical agent used for the treatment of external genital warts and perianal warts. ...
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, ... Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic ...
... and specific anti-neoplastic agents (2020-2025 Outlook)-Manufacturing & Markets Report. Equipment Type: Anti-neoplastic agents ... 2019 Global Forecast for Anti-neoplastic agents, including radioactive isotopes, ... Equipment Type: Anti-neoplastic agents, including radioactive isotopes, and specific antineoplastic. agents. Industry: ... The 2019 Global Forecast for Anti-neoplastic agents, including radioactive isotopes, and specific anti-neoplastic agents (2020- ...
Merck & Co., Inc., Kenilworth, NJ, USA is a global healthcare leader working to help the world be well. From developing new therapies that treat and prevent disease to helping people in need, we are committed to improving health and well-being around the world. The Merck Veterinary Manual was first published in 1955 as a service to the community. The legacy of this great resource continues as the Merck Veterinary Manual in the US and Canada and the MSD Manual outside of North America.. ...
9 Studies found for: Ovarian Germ Cell Cancer , Antineoplastic Agents, Phytogenic. Also searched for Malignant Ovarian Germ ...
Enhanced immune system activation after treatment with novel antineoplastic platinum agents.. Muenchen HJ1, Aggarwal SK. ...
What is antineoplastic agent? Meaning of antineoplastic agent medical term. What does antineoplastic agent mean? ... Looking for online definition of antineoplastic agent in the Medical Dictionary? antineoplastic agent explanation free. ... antineoplastic agent. antineoplastic agent,. n a drug that prevents the development, maturation, or spread of neoplastic cells. ... Prevalence of antineoplastic agent use was estimated from the literature.. Occupational exposures to antineoplastic drugs and ...
Antitumor agent, displays a spectrum of antineoplastic activity including… ... Antitumor agent, displays a spectrum of antineoplastic activity including inhibition of DNA replication and transcription, and ...
... broad spectrum antineoplastic agent. Achieve your results faster with highly validated, pure and trusted compounds. ...
Antineoplastic agentsThese agents inhibit cell growth and proliferation. They are used for chemotherapy.Gemcitabine (Gemzar)A ... Antineoplastic agents. These agents inhibit cell growth and proliferation. They are used for chemotherapy. ... Which medications in the drug class Antineoplastic agents are used in the treatment of Pancreatic Cancer?. Updated: Jan 10, ... This agent is pharmacologically classified as a human epidermal growth factor receptor type 1/epidermal growth factor receptor ...
This study covers the world outlook for anti-neoplastic pharmaceutical agents across more than 190 countries. For each year ... Anti-neoplastic pharmaceutical agents is specifically defined as follows:. 3254121176 Anti-neoplastic agents, including ... In order to estimate the latent demand for anti-neoplastic pharmaceutical agents on a worldwide basis, I used a multi-stage ... Based on the aggregate view of anti-neoplastic pharmaceutical agents as defined above, data were then collected for as many ...
of Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents. 121. PubMed ...
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to ... Antineoplastic; Antineoplastic Alkylating Agents; Antineoplastic Drugs, Alkylating; Antineoplastics, Alkylating; Antineoplastic ... Alkylating Antineoplastic Agents. Subscribe to New Research on Alkylating Antineoplastic Agents A class of drugs that differs ... Antineoplastic Agents, Alkylating; Alkylating Antineoplastic Drugs; Alkylating Antineoplastics; Alkylating Drugs, ...
Antineoplastic Agents;. *Antineoplastic Agents, Alkylating;. *Antineoplastic Agents, Phytogenic;. *Antineoplastic Combined ... Antineoplastic Agents;. *Antineoplastic Agents, Alkylating;. *Antineoplastic Agents, Phytogenic;. *Antineoplastic Combined ...
You are at: Home » Products » Pharmaceuticals and Biochemicals » Antineoplastics agentsIn total 717054 number ofProductsinfo, ...
Antineoplastic Agents products for sale from more than 13836 Antineoplastic Agents manufacturers and Antineoplastic Agents ... Antineoplastic Agents. All Antineoplastic Agents wholesalers & Antineoplastic Agents manufacturers come from members. We ... doesnt provide Antineoplastic Agents products or service, please contact them directly and verify their companies info ...
  • The adverse health effects associated with antineoplastic agents (cancer chemotherapy drugs, cytotoxic drugs) in cancer patients and some non-cancer patients treated with these drugs are well documented. (cdc.gov)
  • Pharmacists who prepare these drugs or nurses who may prepare and/or administer them are the two occupational groups who have the highest potential exposure to antineoplastic agents. (cdc.gov)
  • The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs. (cdc.gov)
  • Additionally, analytical methods have been used to document worker exposure to antineoplastic agents by measuring these drugs and/or their metabolites in the urine of health care workers. (cdc.gov)
  • Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings, 2004 pdf icon (DHHS (NIOSH) Publication No. 2004-165) . (cdc.gov)
  • Currently, there are more than sixty oral antineoplastic drugs available, 22 of which are oral kinase inhibitors that have gained worldwide approval since 2001 [ 1 ]. (hindawi.com)
  • Experts now estimate that more than one-quarter of the 400 antineoplastic agents now under development are planned as oral drugs [ 2 - 4 ]. (hindawi.com)
  • Several surveys have shown that most patients prefer oral antineoplastic drugs to intravenous treatment primarily for the convenience of a home-based therapy and ease of use [ 2 , 3 ]. (hindawi.com)
  • A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. (curehunter.com)
  • According to a new study funded by the National Institute for Occupational Safety and Health (NIOSH) and published online in the Journal of Occupational and Environmental Hygiene, researchers have found that healthcare workers do not always follow recommended safe handling practices for the administration of antineoplastic drugs in healthcare settings . (oncologynurseadvisor.com)
  • Healthcare workers do not always follow recommended safe handling practices for antineoplastic drugs. (oncologynurseadvisor.com)
  • A new National Institute for Occupational Safety and Health (NIOSH) study, published online in the Journal of Occupational and Environmental Hygiene, found that recommended safe handling practices for workers who administer antineoplastic drugs in healthcare settings are not always followed. (oncologynurseadvisor.com)
  • This paper presents findings on current administrative and engineering control practices, personal protective equipment (PPE), and barriers to using recommended PPE during administration of antineoplastic drugs by nearly 2,100 oncology nurses and other healthcare personnel who completed a module addressing antineoplastic drug administration. (oncologynurseadvisor.com)
  • Valley Cottage, NY -- ( SBWIRE ) -- 02/25/2019 -- Anti-neoplastic pharmaceutical agents are the drugs which prevent or inhibit the maturation and proliferation of neoplasms and thus helps in the management of cancer. (sbwire.com)
  • Thus, growing demand for anti-neoplastic pharmaceutical agents has captured the attention of pharmaceutical companies to enter into anti-neoplastic pharmaceutical agents market and develop more efficient drugs against several cancer conditions. (sbwire.com)
  • Geographically, North America followed by Europe dominates the global anti-neoplastic pharmaceutical agents owing high prevalence of cancer cases and increasing demand of drugs for cancer treatment. (sbwire.com)
  • Most antineoplastic drugs target what activity? (brainscape.com)
  • The aim of this study was to review the literature regarding the external contamination of commercial vials by antineoplastic drugs. (bmj.com)
  • Detoxifying agents for antineoplastic treatment and its peer markets - Wireless Health , Tissue adhesives , Iron chelating agents , Next Generation Sequencing (NGS) , Other therapeutic products , Chromatography , Nerve depressants , Chromatography Instruments , Drugs for treatment of hypercalcemia and 11 other markets - adds up to total All other therapeutic products market. (micromarketmonitor.com)
  • Antineoplastic agents are basically drugs used in cancer treatment. (workoutforfatloss.com)
  • Antineoplastic agents are drugs used in cancer treatment that can inhibit the growth and the development of a neoplasm, or the abnormal mass of tissues. (workoutforfatloss.com)
  • Antineoplastic drugs are specifically used to destroy or inhibit the growth of neoplasms. (workoutforfatloss.com)
  • Apart from the cancer patients receiving antineoplastic agents, nurses, hospital technicians, as well as pharmacists handling these drugs may experience the aforementioned side effects due to long-term exposure. (workoutforfatloss.com)
  • Anthracyclines are effective antineoplastic drugs that are widely used in clinical practice. (usda.gov)
  • Antineoplastic agents are used in cytotoxic drugs and cancer chemotherapy drugs. (hoffmannworkcomp.com)
  • The pharmacists who prepare the drugs using these agents can suffer due to contact with them. (hoffmannworkcomp.com)
  • The workers who handle the packaging and shipping of the drugs may accidentally come into contact with the agents and expose themselves to the harmful effect of the antineoplastic agents. (hoffmannworkcomp.com)
  • This page includes surveys conducted by researchers and organizations on handling procedures used when working with antineoplastic drugs. (unt.edu)
  • The sample may have been biased as many patients receiving treatments frequently associated with drug-induced hyperpigmentation, such as antineoplastic drugs, are diagnosed and treated by other specialties, such as oncologists. (jabfm.org)
  • A great number of antineoplastic drugs (ANPDs) are used globally in cancer treatment. (asstsas.com)
  • Cavallo D., Ursini CL, Omodeo-Salé E, Iavicoli S. Micronucleus induction and FISH analysis in buccal cells and lymphocytes of nurses administering antineoplastic drugs. (unt.edu)
  • Using PPE to prevent occupational exposure to antineoplastic and other hazardous drugs. (unt.edu)
  • Fransman W, Huizer D, Tuerk J. Inhalation and dermal exposure t eight antineoplastic drugs in an industrial laundry facility. (unt.edu)
  • Fransman W, Peelen S, Hilhorst S, Roeleveld N, Heederik D, Kromhout H. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. (unt.edu)
  • Fransman W, Roeleveld N, Peelen S, Kort de W, Kromhout H, Heedrik D. Nurses with dermal exposure to antineoplastic drugs Reproductive Outcomes. (unt.edu)
  • Environmental and biologocal monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. (unt.edu)
  • Ikeda K, Yagi Y, Tkegami M, Lu Y, Morimoto K, Kurokawa N. Efforts to ensure safety of hospital pharmacy personnel occupationally exposed to antineoplastic drugs during a preparation task. (unt.edu)
  • Many alkylating agents are pro-drugs which are converted into an active metabolite in the body. (greek.doctor)
  • Drugs of this group are related to mustard gas, a chemical warfare agent. (greek.doctor)
  • Due to the increased costs associated with oral antineoplastic agents, many pharmacy benefit plans have implemented cost-containment mechanisms [ 3 , 7 ]. (hindawi.com)
  • Principles of safe handling of antineoplastic agents. (edcan.org.au)
  • This page includes guideline for the safe handling of antineoplastic agents from professional organizations, government agencies and international groups. (unt.edu)
  • This page lists reviews of the literature published on the topic of safe handling of antineoplastic agents which provide background information on the topic. (unt.edu)
  • Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others.The global Anti - Neoplastic Agents market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. (amarketforecast.com)
  • The effect of pretreatment with anguidine on the cytotoxicity of subsequently administered various chemotherapeutic agents, hyperthermia, and radiation was investigated. (aacrjournals.org)
  • Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. (wikimd.org)
  • R-(-)-gossypol acetic acid - The orally bioavailable solvate of the R-(-) enantiomer of gossypol and acetic acid with potential antineoplastic activity. (wikimd.org)
  • Racemetyrosine/methoxsalen/phenytoin/sirolimus sm-88 - A combination agent containing racemetyrosine, methoxsalen, phenytoin and sirolimus, with potential antineoplastic activity. (wikimd.org)
  • Radgocitabine - An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. (wikimd.org)
  • Nab-paclitaxel/rituximab-coated nanoparticle ar160 - A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. (wikimd.org)
  • Nadofaragene firadenovec - A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. (wikimd.org)
  • Nadofaragene firadenovec/syn3 - A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN alpha-2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. (wikimd.org)
  • The purpose of this brochure is to make you aware of the adverse health effects of antineoplastic agents, describe how you can be exposed to these agents, and provide and identify control methods and work practices to prevent or reduce your exposure to antineoplastic agents. (cdc.gov)
  • However, for the health care workers who are exposed to antineoplastic agents as part of their work practice, precautions should be taken to eliminate or reduce exposure as much as possible. (cdc.gov)
  • A number of studies have documented environmental and worker exposure to the antineoplastic agents. (cdc.gov)
  • Healthcare workers and oncology nurses should be fully aware of the hazards associated with not following these guidelines and the precautionary measures that can be used to minimize exposure to antineoplastic agents. (oncologynurseadvisor.com)
  • These agents are considered cytotoxins, mutagens, and carcinogens, and hence, their proper handling is important to reduce occupational exposure. (workoutforfatloss.com)
  • Occupational exposure to antineoplastic agents can have a dangerous impact on those who handle them. (hoffmannworkcomp.com)
  • This increases the exposure of the workers to these agents. (hoffmannworkcomp.com)
  • Research has shown that exposure to antineoplastic agents is harmful for the environment and the workers. (hoffmannworkcomp.com)
  • They are likely to suffer the most due to exposure to these antineoplastic agents. (hoffmannworkcomp.com)
  • If you have suffered health problems due to exposure to antineoplastic agents in the workplace, you should discuss your rights with a St. Louis worker injury lawyer . (hoffmannworkcomp.com)
  • This page contains articles published within the past three years on all topics related to occupational exposure to antineoplastic agents. (unt.edu)
  • The acute effects associated with exposure to antineoplastic agents, such as skin rashes, allergic-type reactions, hair loss and others, are included in the publications listed in this page. (unt.edu)
  • Important exposure controls for protection against antineoplastic agents: Highlights for oncology health care workers. (asstsas.com)
  • Hypersensitivity to a chemotherapeutic agent is defined as an unforeseen reaction whose signs and symptoms cannot be explained by the known toxicity of the drug [ 29 ]. (hindawi.com)
  • We report a case of pulmonary toxicity associated with the relatively new antineoplastic agent topotecan. (thefreedictionary.com)
  • The selective cytotoxicity displayed by these conjugates towards tested cancer cells with non-toxicity against normal human VERO cells indicated their potential for further antineoplastic drug development. (eurekaselect.com)
  • Thus, it appears that the two opposite effects of anguidine modification of cell kill by cytotoxic agents (protection and potentiation) come about by two different mechanisms, with cell cycle arrest underlying cytoprotection and the mechanism of synergistic toxicity remaining obscure. (aacrjournals.org)
  • However, the use of cisplatin as an anticancer agent is limited due to toxicity and resistance problems. (uwc.ac.za)
  • Carmofur is one of the masked compounds of 5-FU, which was modified for more potent antineoplastic activity and less toxicity. (invivochem.com)
  • Combining multiple antitumor agents increases the cytotoxicity against cancer cells without necessarily increasing the general toxicity. (greek.doctor)
  • A new research study has been presented by UpMarketResearch.com offering a comprehensive analysis on the Global Anti - Neoplastic Agents Market where user can benefit from the complete market research report with all the required useful information about this market. (openpr.com)
  • This segmentation sheds light on the sales of the Anti - Neoplastic Agents on regional- and country-level. (openpr.com)
  • The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Anti - Neoplastic Agents sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. (openpr.com)
  • This study provides Anti - Neoplastic Agents sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020. (openpr.com)
  • Our report helps readers decipher the current and future constraints in the Anti - Neoplastic Agents Market, and help them formulate optimum business strategies to maximize growth in the market. (openpr.com)
  • The 2019 Global Forecast for Anti-neoplastic agents, including radioactive isotopes, and specific anti-neoplastic agents (2020-2025 Outlook)-Manufacturing & Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 140 countries. (bccresearch.com)
  • Anti-neoplastic agents are used prominently as a first line therapy for cancer treatment as well as in combination with surgery or radiation therapy. (cyberessays.com)
  • Plenty of anti-neoplastic agents are available commercially for the treatment of different types of cancers including Oncotrex, Gleevec, Neosar, Cytarine, Leukeran etc. (cyberessays.com)
  • Factors such as growing incidence of cancer across the globe and demand for cost-effective treatment options are believed to play crucial role for the growth of global anti-neoplastic agents market. (cyberessays.com)
  • Anti-neoplastic agents do not get stabilized in one part of the body, however they travel through body and help in destruction of cancerous cells. (sbwire.com)
  • In this report, the global Anti-Neoplastic Agents market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. (qyresearchreports.com)
  • In the recent times, the global market for Global anti neoplastic agents market research report 2017 has surfaced as one of the most promising markets in the pharmaceutical industry, thanks to the significant rise in research and development activities by leading vendors of Global anti neoplastic agents market research report 2017 across the world. (qyresearchreports.com)
  • Manufacturers have turned to technological innovations and data-driven customization to satisfy the augmenting consumer demand for efficiency and more accuracy in results, leading to an increased usage of technology in the Global anti neoplastic agents market research report 2017 production processes, which is also reflecting positively on the growth of this market. (qyresearchreports.com)
  • The research report on the Global anti neoplastic agents market research report 2017 is an analytical study which comprehensively analyzes the competitive framework of this market. (qyresearchreports.com)
  • Using a number of effective assessment tools, such as porter's five forces and value chain analysis, it performs in-depth analyses of the production and supply as well as the demand and sales of Global anti neoplastic agents market research report 2017 and provides deep insights into the future prospects of this market. (qyresearchreports.com)
  • The study begins with a detailed overview of the market for Global anti neoplastic agents market research report 2017, including the definition, classification, and industry chain structure of Global anti neoplastic agents market research report 2017, and move forward to cover every aspect of this market, counting several criteria based on which the market is classified. (qyresearchreports.com)
  • With chemical industry undergoing a phase of technological disruption, innovations in products are likely to shape the future of the Global anti neoplastic agents market research report 2017. (qyresearchreports.com)
  • Further, it offers an estimation of the market size in terms of value (US$) and in volume (kilo tons) and talks about the key segments and the geographical subdivisions of the market for Global anti neoplastic agents market research report 2017 in details. (qyresearchreports.com)
  • It provides in-depth information on the development trends and the policies and regulations, concerning Global anti neoplastic agents market research report 2017, implemented in each of the geographical segments. (qyresearchreports.com)
  • The predominant applications of the Global anti neoplastic agents market research report 2017 have also been discussed at length in this research study. (qyresearchreports.com)
  • With all these analyses and information, this report can act as a valuable guide to readers looking to gain a clear understanding of all the factors that are influencing the market for Global anti neoplastic agents market research report 2017 at present and are projected to remain doing so over the forecast period. (qyresearchreports.com)
  • According to GlobalData's report, ' Diabetic Retinopathy: Global Drug Forecast and Market Analysis to 2029 ', combined sales of two anti-neoplastic agents: ziv-aflibercept and imatinib mesylate, are projected to climb from $19m in 2024 to $75m in 2026. (globaldata.com)
  • The size of the Global Anti-neoplastic Agents Market is estimated to grow at a CAGR of 8.3% from 2019 to 2024. (marketdataforecast.com)
  • Anti-neoplastic Agents are the first line of treatment for cancer. (marketdataforecast.com)
  • However, the high manufacturing costs of anti-neoplastic agents is the major factor hampering the Anti-neoplastic Agents Market growth. (marketdataforecast.com)
  • This research report on the Global Anti-neoplastic Agents Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024. (marketdataforecast.com)
  • The Global Anti-neoplastic Agents market was dominated by North America closely followed Europe. (marketdataforecast.com)
  • This report focuses on Anti - Neoplastic Agents volume and value at global level, regional level and company level. (amarketforecast.com)
  • From a global perspective, this report represents overall Anti - Neoplastic Agents market size by analyzing historical data and future prospect.Regionally, this report categorizes the production, apparent consumption, export and import of Anti - Neoplastic Agents in North America, Europe, China, Japan, Southeast Asia and India. (amarketforecast.com)
  • For each manufacturer covered, this report analyzes their Anti - Neoplastic Agents manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market. (amarketforecast.com)
  • These studies demonstrated the feasibility of employing a PLGA-based microparticulate system as an effective biodegradable, injectable, depot-forming therapeutic system for long-term administration of anti-neoplastic agents. (elsevier.com)
  • Among the antineoplastic agents employed in this project, cyclophosphamide, etoposide, vinblastine and vincristine were potently inhibited the CYP3A4, 2C19 and 2D6 mediated oxidative drug metabolism determined by the typical substrates corresponding to each CYP enzyme. (nii.ac.jp)
  • Alkylating agents like cyclophosphamide alkylates and damages DNA. (greek.doctor)
  • Cyclophosphamide is the most commonly used alkylating agent. (greek.doctor)
  • Antineoplastic Agents therapeutic use. (illinois.edu)
  • In the Anatomical Therapeutic Chemical Classification System , alkylating agents are classified under L01A. (chemeurope.com)
  • Two trace (0.7 and 2.2×10 -7 % yields) potent antineoplastic macrocyclic lactones termed spongistatins 8 (2a) and 9 (2b) have been isolated from the African marine sponge Spirastrella spinispirulifera and found to be very potent inhibitors of glutamate-induced tubulin polymerization. (elsevier.com)
  • Current chemotherapy and infectious disease : proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, 1-5 October 1979 / editors, John D. Nelson, Carlo Grassi. (who.int)
  • A synthetic estrogen that has been used as a hormonal antineoplastic agent. (drugbank.com)
  • Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
  • This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications. (jefferson.edu)
  • Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles. (jefferson.edu)
  • On the other hand, alkylating agents such as cisplatin, cis- [PtCl2 (NH3) 2] have been widely used as antineoplastic agents for a wide variety of cancers including testicular, ovarian, neck and head cancers, amongst others. (uwc.ac.za)
  • On the other hand the newly synthesized palladium complexes also need further evaluation to see if they can be used as anticancer agents that can overcome the problems associated with cisplatin. (uwc.ac.za)
  • The aim of this paper is to provide recent data concerning hypersensitivity reactions to platinum-containing chemotherapy agents. (hindawi.com)
  • Background Currently, oral antineoplastic agents (OAA) represent approximately 40% of all chemotherapy agents. (ovid.com)
  • Most chemotherapy agents interfere with what carcinogenesis phase? (brainscape.com)
  • They are specially designed chemotherapy agents that can attack the rapidly proliferating cancerous cells. (workoutforfatloss.com)
  • These chemotherapy agents were first used in 1940. (workoutforfatloss.com)
  • These chemotherapy agents can attack the healthy cells of the body, while destroying the abnormal cancerous cells. (workoutforfatloss.com)
  • Antitumor agent, displays a spectrum of antineoplastic activity including inhibition of DNA replication and transcription, and the induction of apoptosis. (abcam.com)
  • Cordycepin, a Natural Antineoplastic Agent, Induces Apoptosis of Breast Cancer Cells via Caspase-dependent Pathways. (sigmaaldrich.com)
  • Taurolidine has significant antineoplastic activity against MM in vitro and in vivo , in part, due to tumor cell apoptosis. (aacrjournals.org)
  • Metastatic pure choriocarcinoma is treated with the same multi-agent chemotherapy regimens used in nonseminomatous germ cell tumors (NSGCTs), which are discussed in a separate article (see Nonseminomatous Testicular Tumors ). (medscape.com)
  • Platinum agents are also effective in pediatric tumors [ 16 , 17 ]. (hindawi.com)
  • Antineoplastic agents that are used to treat hormone-sensitive tumors. (drugbank.ca)
  • Anti-Neoplastic pharmaceutical agents are used in combination with surgery, immunotherapy, radiotherapy, hormone therapy, targeted therapy for many solid tumors, especially metastatic. (sbwire.com)
  • It also prevents the tumors from developing resistance to individual agents. (greek.doctor)
  • Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (drugbank.ca)
  • Here, we report that the antineoplastic agents, daunorubicin hydrochloride, etoposide, and vincristine sulfate inhibited the ability of 1,25(OH) 2 D 3 to cause the accumulation of mRNA for kidney 25-hydroxyvitamin D 3 24-hydroxylase (CYP24), an enzyme which catabolizes this hormone. (aacrjournals.org)
  • Our data show that daunorubicin hydrochloride, etoposide, and vincristine sulfate, three well-characterized antineoplastic agents, caused the accumulation of 1,25(OH) 2 D 3 in kidney cells. (aacrjournals.org)
  • Etoposide is an antineoplastic agent used for treating lung cancer, testicular cancer, breast cancer, pediatric cancers, and lymphomas. (springer.com)
  • A new research document with title 'Global and Chinese Antineoplastic Agent Industry , 2017 Market Research Report' covering detailed analysis, Competitive landscape, forecast and strategies. (beforeitsnews.com)
  • The report then estimates 2017-2022 market development trends of Antineoplastic Agent industry. (beforeitsnews.com)
  • Research conducted by the NIOSH shows that the antineoplastic agents are harmful for the cancerous cells but they harm the healthy cells and tissues also. (hoffmannworkcomp.com)
  • 2016 Global Antineoplastic and Immunomodulating Agents Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Antineoplastic and Immunomodulating Agents industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China). (bigmarketresearch.com)
  • This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. (wikimd.org)
  • What is the dermatologic preoperative evaluation and management of antineoplastic and immunosuppressive agents? (medscape.com)
  • Many antineoplastic and immunosuppressive agents have been thought to retard wound healing. (medscape.com)
  • However, the use of immunosuppressive or antineoplastic agents may predispose the patient to an even greater risk of infection, and physicians may consider the use of prophylactic antibiotics. (medscape.com)
  • What is the definition of Antineoplastic and immunosuppressive agents? (dictionary.net)
  • Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. (pharmacycode.com)
  • Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. (pharmacycode.com)
  • Nab-paclitaxel - A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. (wikimd.org)
  • Cell-cycle nonspecific antineoplastic agents (CCNS) refer to a class of pharmaceuticals that act as antitumor agents at all or any phases of the cell cycle. (wikipedia.org)
  • To investigate whether both anguidine-induced potentiation and protection of cells by different antitumor agents were due to its induction of complete suspension of cycle traverse, experiments were also conducted with plateau-phase cultures. (aacrjournals.org)
  • For example, adriamycin, one of the most active antineoplastic agents, is a glycosidic anthracycline antibiotic that is a fermentation product of the fungus, Streptomyces peucetius var. (justia.com)
  • N,n-dibenzyl daunomycin - The N-alkylated analogue of the anthracycline antineoplastic antibiotic daunomycin. (wikimd.org)
  • For cancer patients with a life-threatening disease, there is certainly a great benefit to treatment with these agents. (cdc.gov)
  • In addition to acute or short-term effects related to treatment with antineoplastic agents, there are a number of long-term or chronic effects that have been identified in patients. (cdc.gov)
  • For the past several decades, cancer treatment has entailed primarily intravenous delivery of antineoplastic agents. (hindawi.com)
  • The use of oral antineoplastic agents for cancer treatment removes the routine and continuous monitoring that was included with intravenous treatment. (hindawi.com)
  • A topical agent used for the treatment of external genital warts and perianal warts. (drugbank.ca)
  • A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer. (drugbank.ca)
  • Docetaxel Injection is an antineoplastic agent intended for the treatment of breast cancer, non-small cell lung cancer ("NSCLC"), prostate cancer, gastric adenocarcinoma, and head and neck cancer. (thefreedictionary.com)
  • Cladribine is an antineoplastic agent that has been approved for the treatment of active hairy cell leukemia. (thefreedictionary.com)
  • SAN DIEGO -- The antineoplastic agent letrozole is a promising alternative to clomiphene citrate as a frontline treatment for ovulation induction, results of a small prospective study suggest. (thefreedictionary.com)
  • Which medications in the drug class Antineoplastic agents are used in the treatment of Pancreatic Cancer? (medscape.com)
  • The data shed light on the possibility of cordycepin being a safe agent for breast cancer treatment. (sigmaaldrich.com)
  • A range of packaging for antineoplastic agents for the treatment of cancers. (recollection.com.au)
  • Detoxifying agents for antineoplastic treatment can be segmented by Submarkets, Ingredients and Applications. (micromarketmonitor.com)
  • which of Detoxifying agents for antineoplastic treatment markets are doing well and which are not? (micromarketmonitor.com)
  • This report provides market sizing and forecast for the Detoxifying agents for antineoplastic treatment market. (micromarketmonitor.com)
  • Role of antineoplastic agents in the treatment and palliation of cancer. (edcan.org.au)
  • The nurses who administer the treatment like chemotherapy may be exposed to the negative influence of the agents. (hoffmannworkcomp.com)
  • Study results offering them as palliative therapy options in cancer or as anticancer agents with high levels of cytotoxicity brought a new approach to combine cancer treatment protocols with these products. (usda.gov)
  • s Closed System for Antineoplastic Agent Administration," was conducted by a team of nurses at the Abramson Cancer Center of the Hospital of the University of Pennsylvania, a National Cancer Institute-designated comprehensive cancer center with more than 55,000 doses of chemotherapy delivered per year. (thefreedictionary.com)
  • Of 2,100 oncology nurses and other healthcare personnel, 80% do not wear two pairs of chemotherapy gloves and 15% do not even wear a single pair during the administration of antineoplastic agents to patients. (oncologynurseadvisor.com)
  • With the average cost of a new oral antineoplastic drug in 2012 approximating $10,000, paying for medications can be a significant out-of-pocket expense and burden for patients. (hindawi.com)
  • In this study had clarify the possibility of the drug-drug interaction with the concomitant administration among the commonly ad antineoplastic agents in routine chemotherapy. (nii.ac.jp)
  • Drug repurposing against COVID-19: focus on anticancer agents. (coviki.org)
  • Like other alkylating agents, chlorambucil is potentially mutagenic, teratogenic, and carcinogenic, and an increased incidence of acute leukaemias and other secondary malignancies has been reported in patients who have received the drug. (pocketdrugguide.com)
  • Presently, there are about 50 antineoplastic agents that have been approved by the Food and Drug Administration of the United States. (workoutforfatloss.com)
  • Calcitriol or 1,25-dihydroxyvitamin D 3 [1,25(OH) 2 D 3 ] and analogues have received much interest as anticancer agents because the secosteroid hormone has shown antitumor activity ( 1 - 3 ). (aacrjournals.org)
  • Interestingly, antineoplastic agents are known to stimulate the activity of MAP kinases ( 12 - 15 ). (aacrjournals.org)
  • Publications] Hua Li, Norimitsu Kurata, Yuki Nishimura, Mariko Iwase, Eiji Uchida and Hajime Yasuhara: 'The effect of antineoplastic agent vinblastine and vincristine on CYP3A4, CYP2C19 and CYP2D6 activity in human liver microsomes'Xenobiotica. (nii.ac.jp)
  • These agents prevent seizure recurrence and terminate clinical and electrical seizure activity. (medscape.com)
  • Na17.A2 Peptide vaccine - A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. (wikimd.org)
  • Additional agents in some regimens or for salvage include vinblastine and ifosfamide. (medscape.com)
  • The clinical trials on this list are studying Antineoplastic Agent Combination SM-88. (cancer.gov)
  • Several new antineoplastic agents are in clinical trials such as Oncofetal Ag (phase 1), Panobinostat (Phase 2), Volasertib (phase 2), Bortezomib (phase 4) etc. which are expected to launch in next 5-10 years. (cyberessays.com)
  • A human epidermal growth factor receptor type 1/epidermal growth factor receptor (HER-1/EGFR) tyrosine kinase inhibitor used in combination with the antineoplastic agent gemcitabine for advanced pancreatic cancer in patients who have not yet received chemotherapy. (thefreedictionary.com)
  • This agent is less cardiotoxic than daunomycin. (wikimd.org)
  • These agents are also known as cytotoxic agents. (sbwire.com)
  • Most cytotoxic agents act upon process of cell growth and division: potent and potentially dangerous. (vetstream.com)